EP1062218A1 - MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) - Google Patents

MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Info

Publication number
EP1062218A1
EP1062218A1 EP99908770A EP99908770A EP1062218A1 EP 1062218 A1 EP1062218 A1 EP 1062218A1 EP 99908770 A EP99908770 A EP 99908770A EP 99908770 A EP99908770 A EP 99908770A EP 1062218 A1 EP1062218 A1 EP 1062218A1
Authority
EP
European Patent Office
Prior art keywords
thieno
alkyl
compound according
arylc
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99908770A
Other languages
German (de)
French (fr)
Inventor
Henrik Sune Andersen
Todd Kevin Jones
Daniel Dale Holsworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Ontogen Corp
Original Assignee
Novo Nordisk AS
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Ontogen Corp filed Critical Novo Nordisk AS
Publication of EP1062218A1 publication Critical patent/EP1062218A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1 B, CD45, SHP-1 , SHP-2, PTP ⁇ , LAR and HePTP or the like,
  • PTPases Protein Tyrosine Phosphatases
  • PTPases plays a major role in the intracellular modulation and regulation of fundamental cellular signalling mechanisms involved in metabolism, growth, proliferation and differentiation (Flint et al., The EMBO J. 12:1937-46 (1993); Fischer et al, Science 253:401-6 (1991)). Overexpression or altered activity of tyrosi- ne phosphatases can also contribute to the symptoms and progression of various diseases (Wiener, et al., J. Natl. cancer Inst. 86:372-8 (1994); Hunter and Cooper, Ann. Rev. Biochem, 54:897-930 (1985)).
  • Protein phosphorylation is now well recognized as an important mechanism utilized by cells to transduce signals during different stages of cellular function (Fischer et al, Science 253:401-6 (1991); Flint et al., The EMBO J. 12:1937-46 (1993)).
  • phosphatases There are at least two major classes of phosphatases: (1) those that dephosphorylate proteins (or peptides) that contain a phosphate group(s) on a serine or threonine moiety (termed Ser/Thr phosphatases) and (2) those that remove a phosphate group(s) from the amino acid tyrosine (termed protein tyrosine phosphatases or PTPases).
  • the PTPases are a family of enzymes that can be classified into two groups: a) intracellular or nontransmembrane PTPases and b) receptor-type or transmembrane PTPases.
  • Intracellular PTPases Most known intracellular type PTPases contain a single conserved catalytic phosphatase domain consisting of 220-240 amino acid residues. The regions outside the PTPase domains are believed to play important roles in localizing the intracellular PTPases subcellularly (Mauro, L.J. and Dixon, J.E. TIBS 19: 151-155 (1994)). The first intracellular PTPase to be purified and characterized was PTP1B which was isolated from human placenta (Tonks et al., J. Biol. Chem. 263: 6722-6730 (1988)). Shortly after, PTP1B was cloned (Charbonneau et al., Proc.
  • intracellular PTPases include (1) T-cell PTPase (Cool et al. Proc. Natl. Aead. Sci. USA 86: 5257-5261 (1989)), (2) rat brain PTPase (Guan et al., Proc. Natl. Aead. Sci. USA 87:1501-1502 (1990)), (3) neuronal phosphatase STEP (Lombroso et al., Proc. Natl. Aead. Sci.
  • LMW-PTPase Low molecular weight phosphotyrosine-protein phosphatase shows very little sequence identity to the intracellular PTPases described above.
  • this enzyme belongs to the PTPase family due to the following characteristics: (i) it possesses the PTPase active site motif: Cys-Xxx-Xxx-Xxx- Xxx-Xxx-Arg (Cirri et al., Eur. J. Biochem. 214: 647-657 (1993)); (ii) this Cys residue forms a phospho-intermediate during the catalytic reaction similar to the situation with 'classical' PTPases (Cirri et al., supra; Chiarugi et al., FEBS Lett.
  • Receptor-type PTPases consist of a) a putative ligand-binding extracellular domain, b) a transmembrane segment, and c) an intracellular catalytic region.
  • the structures and sizes of the putative ligand-binding extracellular domains of receptor-type PTPases are quite divergent.
  • the intracellular catalytic regions of receptor-type PTPases are very homologous to each other and to the intracellular PTPases.
  • Most receptor-type PTPases have two tandemly duplicated catalytic PTPase domains.
  • the first receptor-type PTPases to be identified were (1) CD45/LCA (Ralph, S.J., EMBO J. 6: 1251-1257 (1987)) and (2) LAR (Streuli et al., J. Exp. Med. 168: 1523-1530 (1988)) that were recognized to belong to this class of enzymes based on homology to PTP1B (Charbonneau et al., Proc. Natl. Aead. Sci. USA 86: 5252- 5256 (1989)).
  • CD45 is a family of high molecular weight glycoproteins and is one 4 of the most abundant leukocyte cell surface glycoproteins and appears to be exclusively expressed upon cells of the hematopoietic system (Trowbridge and Thomas, Ann. Rev. Immunol. 12: 85-116 (1994)).
  • PTPa,_PTPe All receptor-type PTPases except Type IV contain two PTPase domains. Novel PTPases are continuously identified, and it is anticipated that more than 500 different species will be found in the human genome, i.e. close to the predicted size of the protein tyrosine kinase superfamily (Hanks and Hunter, FASEB J. 9: 576-596 (1995)).
  • PTPases are the biological counterparts to protein tyrosine kinases (PTKs). Therefore, one important function of PTPases is to control, down-regulate, the activity of PTKs.
  • PTKs protein tyrosine kinases
  • a more complex picture of the function of PTPases now emerges.
  • Several studies have shown that some PTPases may actually act as positive mediators of cellular signalling.
  • the SH2 domain- containing PTP1 D seems to act as a positive mediator in insulin-stimulated Ras activation (Noguchi et al., Mol. Cell. Biol. 14: 6674-6682 (1994)) and of growth 5 factor-induced mitogenic signal transduction (Xiao et al., J. Biol. Chem.
  • PTPases as positive regulators has been provided by studies designed to define the activation of the Src-family of tyrosine kinases. In particular, several lines of evidence indicate that CD45 is positively regulating the activation of hematopoietic cells, possibly through dephosphorylation of the C-terminal tyrosine of Fyn and Lck (Chan et al., Annu. Rev. Immunol. 12: 555-592 (1994)).
  • Dual specificity protein tyrosine phosphatases define a subclass within the PTPases family that can hydrolyze phosphate from phosphortyrosine as well as from phosphor-serine/threonine.
  • dsPTPases contain the signature sequence of PTPases: His-Cys-Xxx-Xxx-Gly-Xxx-Xxx-Arg. At least three dsPTPases have been shown to dephosphorylate and inactivate extracellular signal-regulated kinase (ERKs)/mitogen-activated protein kinase (MAPK): MAPK phosphatase (CL100, 3CH134) (Charles et al., Proc. Natl.
  • dsPTPases Transcription of dsPTPases are induced by different stimuli, e.g. oxidative stress or heat shock (Ishibashi et ai, J. Biol. Chem. 269: 29897-29902 (1994); Keyse and Emslie, Nature 359: 644-647 (1992)).
  • stimuli e.g. oxidative stress or heat shock (Ishibashi et ai, J. Biol. Chem. 269: 29897-29902 (1994); Keyse and Emslie, Nature 359: 644-647 (1992)).
  • cdc25 Millar and Russell, Cell 68: 407-410 (1992)
  • KAP Hannon et al., Proc. Natl. Aead. Sci. USA 91: 1731-1735 (1994)
  • tyrosine dephosphorylation of cdc2 by a dual specific phosphatase, cdc25 is required for induction of mitosis in yeast (review by Walton and Dixon, Annu. Rev. Biochem. 62: 101-120 (1993)).
  • PTPases were originally identified and purified from cell and tissue lysates using a variety of artificial substrates and therefore their natural function of dephosphorylati- on was not well known. Since tyrosine phosphorylation by tyrosine kinases is usually 6 associated with cell proliferation, cell transformation and cell differentiation, it was assumed that PTPases were also associated with these events. This association has now been proven to be the case with many PTPases.
  • PTP1B a phosphatase whose structure was recently elucidated (Barford et al., Science 263:1397-1404 (1994)) has been shown to be involved in insulin-induced oocyte maturation (Flint et al., The EMBO J.
  • PTPases the insulin receptor signalling pathway/diabetes
  • Insulin is an important regulator of different metabolic processes and plays a key role in the control of blood glucose. Defects related to its synthesis or signalling 7 lead to diabetes mellitus. Binding of insulin to its receptor causes rapid (auto)phosphorylation of several tyrosine residues in the intracellular part of the b- subunit. Three closely positioned tyrosine residues (the tyrosine-1150 domain) must all be phosphorylated to obtain full activity of the insulin receptor tyrosine kinase (IRTK) which transmits the signal further downstream by tyrosine phosphorylation of other cellular substrates, including insulin receptor substrate-1 (IRS-1) (Wilden et al., J. Biol. Chem.
  • IRTK appears to be tightly regulated by PTP- mediated dephosphorylation in vivo (Khan et al., J. Biol. Chem. 264: 12931-12940 (1989); Faure et al., J. Biol. Chem. 267: 11215-11221 (1992); Rothenberg et al., J. Biol. Chem. 266: 8302-8311 (1991)).
  • PTPases have distinct structural features that determine their subcellular localization and thereby their access to defined cellular substrates (Frangione et ai, Cell 68: 545-560 (1992); Faure and Posner, Glia 9: 311-314 (1993)).
  • PTP1 B and TC-PTP may, at least in part, be explained by the fact that they do not co-localize with the activated insulin receptor.
  • PTP1B and TC-PTP have been excluded as candidates for the IR-associated PTPases in hepatocytes based on subcellular localization studies (Faure et ai, J. Biol. Chem. 267: 11215-11221 (1992)).
  • the transmembrane PTPase CD45 which is believed to be hematopoietic cell- specific, was in a recent study found to negatively regulate the insulin receptor tyrosine kinase in the human multiple myeloma cell line U266 (Kulas et ai, J. Biol. Chem. 271: 755-760 (1996)). 10
  • Somatostatin inhibits several biological functions including cellular proliferation (Lamberts et al., Molec. Endocrinoi 8: 1289-1297 (1994)). While part of the antiproliferative activities of somatostatin are secondary to its inhibition of hormone and growth factor secretion (e.g. growth hormone and epidermal growth factor), other antiproliferative effects of somatostatin are due to a direct effect on the target cells. As an example, somatostatin analogs inhibit the growth of pancreatic cancer presumably via stimulation of a single PTPase, or a subset of PTPases, rather than a general activation of PTPase levels in the cells (Liebow et ai, Proc. Natl. Aead.
  • PTPases the immune system/autoimmunity
  • CD45 is one of the most abundant of the cell surface glycoproteins and is expressed exclusively on hemopoetic cells. In T cells, it has been shown that CD45 is one of the critical components of the signal transduction machinery of lymphocytes. In particular, evidence has suggested that CD45 phosphatase plays a pivotal role in antigen- stimulated proliferation of T lymphocytes after an antigen has bound to the T cell receptor (Trowbridge, Ann. Rev. Immunol, 12:85-116 (1994)). Several studies suggest 11 that the PTPase activity of CD45 plays a role in the activation of Lck, a lymphocyte- specific member of the Src family protein-tyrosine kinase (Mustelin etal., Proc. Natl. Aead.
  • the p56lck-CD45 interaction seems to be mediated via a nonconventional SH2 domain interaction not requiring phosphotyrosine.
  • Fyn another member of the Src family protein-tyrosine kinases, Fyn, seems to be a selective substrate for CD45 compared to Lck and Syk (Katagiri et al., J. Biol. Chem. 270: 27987-27990 (1995)).
  • CD45 has also been shown to be essential for the antibody mediated degranulation of mast cells (Berger et al., J. Exp. Med. 180:471-6 (1994)). These studies were also done with mice that were CD45-def ⁇ cient. In this case, an IgE-mediated degranulation was demonstrated in wild type but not CD45-deficient T cells from mice. These data suggest that CD45 inhibitors could also play a role in the symptomatic or therapeutic treatment of allergic disorders.
  • HePTP lymphoid-specific protein tyrosine phosphatase
  • HePTP may function during sustained stimulation to modulate the immune response through dephosphorylation of specific residues. Its exact role, however remains to be defined.
  • PTPase inhibitors may be attractive drug candidates both as immunosuppressors and as immunostimulants.
  • BMLOV vanadium-based PTPase inhibitor
  • PTPases cell-cell interactions/cancer
  • Focal adhesion plaques an in vitro phenomenon in which specific contact points are formed when fibroblasts grow on appropriate substrates, seem to mimic, at least in part, cells and their natural surroundings.
  • Several focal adhesion proteins are phosphorylated on tyrosine residues when fibroblasts adhere to and spread on extracellular matrix (Gumbiner, Neuron 11, 551-564 (1993)).
  • Aberrant tyrosine phosphorylation of these proteins can lead to cellular transformation.
  • the intimate association between PTPases and focal adhesions is supported by the finding of several intracellular PTPases with ezrin-like N-terminal domains, e.g. PTPMEG1 (Gu et ai, Proc. Natl. Aead. Sci.
  • PTPH1 Yang and Tonks, Proc. Natl. Aead. Sci. USA 88: 5949-5953 (1991)
  • PTPD1 Yang and Tonks, Proc. Natl. Aead. Sci. USA 88: 5949-5953 (1991)
  • PTPD1 M ⁇ ller et al., Proc. Natl. Aead. Sci. USA 91: 7477-7481 (1994)
  • the ezrin-like domain show similarity to several proteins that are believed to act as links between the cell membrane and the cytoskeleton.
  • PTPD1 was found to be phosphorylated by and associated with c-src in vitro and is hypothesized to be involved in the regulation of phosphorylation of focal adhesions (M ⁇ ller et ai, supra). 13
  • PTPases may oppose the action of tyrosine kinases, including those responsible for phosphorylation of focal adhesion proteins, and may therefore function as natural inhibitors of transformation.
  • TC-PTP and especially the truncated form of this enzyme (Cool et ai, Proc. Natl. Aead. Sci. USA 87: 7280-7284 (1990)), can inhibit the transforming activity of v-erb and v-fms (Lammers et ai, J. Biol. Chem. 268: 22456-22462 (1993); Zander et ai, Oncogene 8: 1175-1182 (1993)).
  • PTP1B The expression level of PTP1B was found to be increased in a mammary cell line transformed with neu (Zhay et ai, Cancer Res. 53: 2272-2278 (1993)).
  • the intimate relationship between tyrosine kinases and PTPases in the development of cancer is further evidenced by the recent finding that PTPe is highly expressed in murine mammary tumors in transgenic mice over-expressing c-neu and v-Ha-ras, but not c-myc or int-2 (Elson and Leder, J. Biol. Chem. 270: 26116-26122 (1995)).
  • PTPases appear to be involved in controlling the growth of fibroblasts.
  • Swiss 3T3 cells harvested at high density contain a membrane-associated PTPase whose activity on an average is 8-fold higher than that of cells harvested at low or medium density (Pallen and Tong, Proc. Natl. Aead. Sci. USA 88: 6996-7000 (1991)). It was hypothesized by the authors that density-dependent inhibition of cell growth involves the regulated elevation of the activity of the PTPase(s) in question.
  • PTPases Two closely related receptor-type PTPases, PTPK and PTP ⁇ , can mediate homophilic cell-cell interaction when expressed in non-adherent insect cells, suggesting that these PTPases might have a normal physiological function in cell- to-cell signalling (Gebbink er a/., J. Biol. Chem. 268: 16101-16104 (1993); Brady- Kalnay er /., J. Cell Biol. 122: 961-972 (1993); Sap et ai, Mol. Cell. Biol. 14: 1-9 (1994)).
  • PTPk and PTP ⁇ do not interact with each other, despite their structural similarity (Zondag et ai, J. Biol. Chem.
  • PTPases may play an important role in regulating normal cell growth.
  • PTPases may also function as positive mediators of intracellular signalling and thereby induce or enhance mitogenic responses. Increased activity of certain PTPases might therefore result in cellular transformation and tumor formation.
  • over-expression of PTP ⁇ was found to lead to transformation of rat embryo fibroblasts (Zheng, supra).
  • SAP-1 a novel PTP, SAP-1 , was found to be highly expressed in pancreatic and colorectal cancer cells.
  • SAP-1 is mapped to chromosome 19 region q13.4 and might be related to carcinoembryonic antigen mapped to 19q13.2 (Uchida et ai, J. Biol. Chem. 269: 12220-12228 (1994)). Further, the dsPTPase, cdc25, dephosphorylates cdc2 at Thr14/Tyr-15 and thereby functions as positive regulator of mitosis (reviewed by Hunter, Cell 80: 225-236 (1995)). Inhibitors of specific PTPases are therefore likely to be of significant therapeutic value in the treatment of certain forms of cancer.
  • PTPases platelet aggregation
  • the rate of bone formation is determined by the number and the activity of osteoblasts, which in term are determined by the rate of proliferation and differentiation of osteoblast progenitor cells, respectively. Histomorphometric studies indicate that the osteoblast number is the primary determinant of the rate of bone formation in humans (Gruber et ai, Mineral Electrolyte Metab. 12: 246-254 (1987); reviewed in Lau etal., Biochem. J. 257: 23-36 (1989)). Acid phosphatases/PTPases may be involved in negative regulation of osteoblast proliferation. Thus, fluoride, which has phosphatase inhibitory activity, has been found to increase spinal bone density in osteoporotics by increasing osteoblast proliferation (Lau ef ai, supra).
  • an osteoblastic acid phosphatase with PTPase activity was found to be highly sensitive to mitogenic concentrations of fluoride (Lau er a/., J. Biol. Chem. 260: 4653-4660 (1985); Lau et ai, J. Biol. Chem. 262: 1389-1397 (1987); Lau et ai, Adv. Protein Phosphatases 4: 165-198 (1987)).
  • the level of membrane-bound PTPase activity was increased dramatically when the 16 osteoblast-like cell line UMR 106.06 was grown on collagen type-l matrix compared to uncoated tissue culture plates.
  • OST-PTP parathyroid regulated, receptor-like PTPase
  • PTPases microorganisms
  • VH1 a dual-specificity phosphatase
  • the present invention relates to compounds of the general formula I, wherein A, R 1 ⁇ R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the detailed part of the present description, wherein such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1 , SHP-2, PTP ⁇ , LAR and HePTP or the like.
  • PTPases Protein Tyrosine Phosphatases
  • the present compounds are useful for the treatment, prevention, elimination, alleviation or amelioration of an indication related to type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the method of treatment may be described as the treatment, prevention, elimination, alleviation or amelioration of one of the above indications, which comprises the step of administering to the said subject a neurologically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
  • a further aspect of the invention relates to the use of a compound of the present invention for the preparation of a pharmaceutical composition for the treatment of all type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizo- phrenia, and infectious diseases.
  • the present invention relates to Compounds of the Formula 1 wherein A, R 1 ( R 2 , R 3 , R 4 , R 16 and R 17 are defined below; 19
  • A is together with the double bond in Formula 1 furo[2,3-b]pyridyl, thieno[2,3- bjpyridyl, pyrrolo[2,3-b]pyridyl, furo[2,3-c]pyridyl, thieno[2,3-c]pyridyl, pyrrolo[2,3- cjpyridyl, furo[3,2-c]pyridyl, thieno[3,2-c]pyridyl, pyrrolo[3,2-c]pyridyl, furo[3,2- djpyridyl, thieno[3,2-d]pyridyl, pyrrolo[3,2-d]pyridyl, furo[2,3-d]pyrimidyl, thieno[2,3- djpyrimidyl, pyrrolo[2,3-d]pyrimidyl, furo[2,3-bjpyrazinyl, thi
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C,- C 6 alkyl, aryl, arylC C 6 alkyl, hydroxy, oxo, carboxy, carboxyC C 6 alkyl, C r Cgalkyloxycarbonyl, aryloxycarbonyi, arylC r C 6 alkyloxycarbonyl, C r C 6 alkyloxy, C r C 6 alkyloxyC,-C 6 alkyl, aryloxy, arylC r C 6 alkyloxy, arylC 1 -C 6 alkyloxyC 1 -C 6 alkyl, thio, C C 6 alkylthio, C 1 -C 6 alkylthioC 1 -C 6 alkyl, arylthio, arylC r C 6 alkylthio, arylC 1 -C 6 alkylthioC 1 - C 6 alkyl
  • R 12 , R 13 , and R 14 are independently hydrogen, C 1 -C 6 alkyl, aryl, arylC 1 -C 6 alkyl and the alkyl and aryl groups are optionally substituted; 22
  • R 4 is hydrogen, hydroxy, C 1 -C 6 alkyl, aryl, arylC ⁇ Cgalkyl, NR 7 R 8 , C C 6 alkyloxy; wherein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C 1 -C 6 alkyl, aryl, arylC 1 -C 6 alkyl, C ⁇ Cgalkyloxy, C 1 -C 6 alkyl-oxyC 1 -
  • R 6 is hydrogen, C ⁇ Cgalkyl, aryl, arylC 1 -C 6 alkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, C C 6 alkyl, aryl, arylC C 6 alkyl, C C 6 alkylcarbonyl, arylcarbonyl, arylC r C 6 alkylcarbonyl, C r C 6 alkylcarboxy or arylC C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R 7 and R 8 are together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing from 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C 1 -C 6 alkyl, aryl, arylC C 6 alkyl, hydroxy, oxo, C r C 6 alkyloxy, arylC C 6 alkyloxy, C 1 -C 6 alkyloxyC 1 -
  • Signal transduction is a collective term used to define all cellular processes that follow the activation of a given cell or tissue.
  • Examples of signal transduction which are not intended to be in any way limiting to the scope of the invention claimed, are cellular events that are induced by polypeptide hormones and growth factors (e.g. insulin, insulin-like growth factors I and II, growth hormone, epidermal growth factor, platelet-derived growth factor), cytokines (e.g. interleukins), extracellular matrix components, and cell-cell interactions.
  • polypeptide hormones and growth factors e.g. insulin, insulin-like growth factors I and II, growth hormone, epidermal growth factor, platelet-derived growth factor
  • cytokines e.g. interleukins
  • Phosphotyrosine recognition units/tyrosine phosphate recognition units/pTyr recognition units are defined as areas or domains of proteins or gly- coproteins that have affinity for molecules containing phosphorylated tyrosine residues (pTyr).
  • Examples of pTyr recognition units which are not intended to be in any way limiting to the scope of the invention claimed, are: PTPases, SH2 domains and PTB domains.
  • PTPases are defined as enzymes with the capacity to dephosphorylate pTyr- containing proteins or glycoproteins.
  • Examples of PTPases which are not intended to be in any way limiting to the scope of the invention claimed, are: 'classical' PTPases (intracellular PTPases (e.g. PTP1B, TC-PTP, PTP1C, PTP1D, PTPD1 , PTPD2) and receptor-type PTPases (e.g. PTP ⁇ , PTP ⁇ , PTP ⁇ , PTP ⁇ , CD45, PTPK, PTP ⁇ ), dual speci- ficty phosphatases (VH1, VHR, cdc25), LMW-PTPases or acid phosphatases.
  • intracellular PTPases e.g. PTP1B, TC-PTP, PTP1C, PTP1D, PTPD1 , PTPD2
  • receptor-type PTPases e.g. PTP ⁇ , P
  • SH2 domains are non-catalytic protein modules that bind to pTyr (phosphotyrosine residue) containing proteins, i.e. SH2 domains are pTyr recognition units. SH2 domains, which consist of ⁇ 100 amino acid residues, are found in a number of different molecules involved in signal transduction processes. The following is a non-limiting list of proteins containing SH2 domains: Src, Hck, Lck, Syk, Zap70, SHP-1 , SHP-2, STATs, Grb-2, She, p85/PI3K, Gap, vav (see Russell et al, FEBS Lett. 24
  • the term "attached” or "-" e.g. -COR ⁇ which indicates the carbonyl attachment point to the scaffold
  • halogen include fluorine, chlorine, bromine, and iodine.
  • alkyl includes C r C 6 straight chain, methylene, saturated and C 2 -C 6 unsaturated aliphatic hydrocarbon groups, C r C 6 branched saturated and C 2 -C 6 unsatu- rated aliphatic hydrocarbon groups, C 3 -C 6 cyclic saturated and C 5 -C 6 unsaturated aliphatic hydrocarbon groups, and C r C 6 straight chain or branched saturated and C 2 - ' C 6 straight chain or branched unsaturated aliphatic hydrocarbon groups substituted with C 3 -C 6 cyclic saturated and unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • this definition shall include but is not limited to methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, heptyl, ethenyl, propenyl, butenyl, penentyl, hexenyl, isopropyl (i-Pr), isobutyl (i-Bu), tert- butyl (f-Bu), sec-butyl (s-Bu), isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopen- tyl, cyclohexyl, cyclopentenyl, cyclohexenyl, methylcyclopropyl, ethylcyclohexenyl, butenylcyclopentyl, and the like.
  • substituted alkyl represents an alkyl group as defined above wherein the substitutents are independently selected from halo, cyano, nitro, trihalomethyl, car- bamoyl, hydroxy, oxo, COR 5 , C Cgalkyl, C r C 6 alkyloxy, aryloxy, arylC r C 6 alkyloxy, thio, C r C 6 alkylthio, arylthio, arylC r C 6 alkylthio, NR 7 R 8 , C r Cgalkylamino, arylamino, arylC r C 6 alkylamino, di(arylC C 6 alkyl)amino, C 1 -C 6 alkylcarbonyl, arylC,- C 6 alkylcarbonyl, C C 6 alkylcarboxy, arylcarboxy, arylC r C 6 alkylcarboxy, C C 6 alkylcarboxy, C
  • R 5 is defined as above or NR 7 R 8 , wherein R 7 , R 8 are defined as above.
  • saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring sy- stem represents but are not limit to aziridinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imida- zolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, 1 ,2,3-triazolyl, 1 ,2,4- triazolyl, morpholinyl, piperidinyl, thiomorpholinyl, piperazinyl, indolyl, isoindolyl, 1 ,2,3,4-tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydro-isoquinolinyl, 1 ,2,3,4-tetrahydro- quinoxalinyl, indolinyl, indazolyl, benzimidazolyl, benzotriazolyl, puriny
  • alkyloxy (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy) represents an "alkyl” group as defined above having the indicated number of carbon atoms attached through an oxygen bridge.
  • alkyloxyalkyl represents an "alkyloxy” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • alkyloxyalkyloxy represents an "alkyloxyalkyl” group attached through an oxygen atom as defined above having the indicated number of carbon atoms.
  • aryloxy e.g. phenoxy, naphthyloxy and the like
  • aryloxy represents an aryl group as defined below attached through an oxygen bridge.
  • arylalkyloxy (e.g. phenethyloxy, naphthylmethyloxy and the like) represents an “arylalkyl” group as defined below attached through an oxygen bridge.
  • arylalkyloxyalkyl represents an "arylalkyloxy” group as defined above at- tached through an "alkyl” group defined above having the indicated number of carbon atoms.
  • arylthio e.g. phenylthio, naphthylthio and the like
  • alkyloxycarbonyl e.g. methylformiat, ethylformiat and the like
  • aryloxycarbonyi e.g. phenylformiat, 2-thiazolylformiat and the like
  • arylalkyloxycarbonyl e.g. benzylformiat, phenyletylformiat and the like
  • alkyloxycarbonylalkyl represents an "alkyloxycarbonyl” group as defined above attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • arylalkyloxycarbonylalkyl represents an "arylalkyloxycarbonyl” group as defined above attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • alkylthio (e.g. methylthio, ethylthio, propylthio, cyclohexenylthio and the like) represents an “alkyl” group as defined above having the indicated number of carbon atoms attached through a sulfur bridge.
  • arylalkylthio (e.g. phenylmethylthio, phenylethylthio, and the like) represents an “arylalkyl” group as defined above having the indicated number of carbon atoms attached through a sulphur bridge.
  • alkylthioalkyl represents an "alkylthio" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • arylalkylthioalkyl represents an "arylalkylthio" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • alkylamino e.g. methylamino, diethylamino, butylamino, N-propyl-N- hexylamino, (2-cyclopentyl)propylamino, hexenylamino, pyrrolidinyl, piperidinyl and the like
  • alkylamino represents one or two "alkyl” groups as defined above having the indicated number of carbon atoms attached through an amine bridge.
  • the two alkyl groups may be taken together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C 27
  • arylalkylamino e.g. benzylamino, diphenylethylamino and the like
  • arylalkylamino represents one or two "arylalkyl” groups as defined above having the indicated number of carbon atoms attached through an amine bridge.
  • the two "arylalkyl” groups may be taken together with the nitrogen to which they are attached forming a saturated, par- tially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C 1 -C 6 alkyl, aryl, arylC r C 6 alkyl, hydroxy, oxo, C ⁇ -Cgalkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, NR 9 R 10 , C . CgalkylaminoC 1 -C 6 alkyl substituent wherein the alkyl and aryl groups are optionally substituted as defined in the definition section and R 9 and R 10 are defined as above.
  • alkylaminoalkyl represents an "alkyiamino” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • arylalkylaminoalkyl represents an "arylalkylamino” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • arylalkyl e.g. benzyl, phenylethyl
  • alkylcarbonyl e.g. cyclooctylcarbonyl, pentylcarbonyl, 3-hexenylcarbonyl
  • alkylcarbonyl represents an "alkyl” group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
  • arylcarbonyl (benzoyl) represents an “aryl” group as defined above attached through a carbonyl group.
  • arylalkylcarbonyl (e.g. phenylcyclopropylcarbonyl, phenylethylcarbonyl and the like) represents an "arylalkyl” group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
  • alkylcarbonylalkyl represents an "alkylearbonyl” group attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • arylalkylcarbonylalkyl represents an "arylalkylcarbonyl” group attached through an alkyl group as defined above having the indicated number of carbon atoms.
  • alkylcarboxy e.g. heptylcarboxy, cyclopropylcarboxy, 3-pentenylcarboxy
  • alkylearbonyl represents an "alkylearbonyl” group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
  • arylcarboxyalkyl (e.g. phenylcarboxymethyl) represents an "arylcarbonyl” group defined above wherein the carbonyl is in turn attached through an oxygen bridge to an alkyl chain having the indicated number of carbon atoms.
  • arylalkylcarboxy (e.g. benzylcarboxy, phenylcyclopropylcarboxy and the like) represents an "arylalkylcarbonyl” group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
  • alkylcarboxyalkyl represents an "alkylcarboxy” group attached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • arylalkylcarboxyalkyl represents an “arylalkylcarboxy” group attached through an “alkyl” group as defined above having the indicated number of carbon atoms.
  • alkylcarbonylamino e.g. hexylcarbonylamino, cyclopentylcarbonyl- aminomethyl, methylcarbonylammophenyl
  • alkylearbonyl represents an "alkylearbonyl” group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group. The nitrogen atom may itself be substituted with an alkyl or aryl group.
  • arylalkylcarbonylamino e.g.
  • benzylcarbonylamino and the like repre- sents an "arylalkylcarbonyl" group as defined above wherein the carbonyl is in turn 29 attached through the nitrogen atom of an amino group.
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • alkylearbonylaminoalkyl represents an "alkylcarbonylamino” group attached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • arylalkylcarbonylaminoalky represents an "arylalkylcarbonylamino” group attached through an "alkyl” group as defined above having the indicated number of carbon atoms.
  • the nitrogen atom may itself be substituted with an alkyl or aryl group.
  • alkylcarbonylaminoalkylcarbonyl represents an alkylearbonylaminoalkyl group attached through a carbonyl group.
  • the nitrogen atom may be further substituted with an "alkyl” or "aryl” group.
  • aryl represents an unsubstituted, mono-, di- or trisubstituted monocyclic, polycyclic, biaryl and heterocyclic aromatic groups covalently attached at any ring position capable of forming a stable covalent bond, certain preferred points of attachment being apparent to those skilled in the art (e.g., 3-indolyl, 4-imidazolyl).
  • the aryl substituents are independently selected from the group consisting of halo, nitro, cyano, trihalomethyl, C 1 -C 6 alkyl, aryl, arylC C 6 alkyl, hydroxy, COR 5 , C C 6 alkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, aryloxy, arylC ⁇ -Cgalkyloxy, arylC 1 -C 6 alkyloxyC 1 -C 6 alkyl, thio, C r C 6 alkylthio, C 1 -C 6 alkylthioC 1 -C 6 alkyl, arylthio, arylC r Cgalkylthio, arylC r CgalkylthioC Cgalkyl, NR 8 R 9 , C 1 -C 6 -alkylamino, C 1 -C 6 alkylaminoC 1 -C 6 alkyl, arylamino,
  • aryl includes but is not limited to phenyl, biphenyl, indenyl, fluorenyl, naphthyl (1-naphthyl, 2-naphthyl), pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imida- zolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazoM-yl, 1,2,3-triazol-2-yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl,
  • arylcarbonyl e.g. 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, oxa- zolylcarbonyl
  • arylcarbonyl represents an "aryl” group as defined above attached through a carbonyl group.
  • arylalkylcarbonyl e.g. (2,3-dimethoxyphenyl)-propylcarbonyl, (2- chloronaphthyl)pentenylcarbonyl, imidazolylcyclo-pentylcarbonyl
  • arylalkylcarbonyl represents an "arylalkyl” group as defined above wherein the "alkyl” group is in turn attached through a carbonyl.
  • the compounds of the present invention have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms being included in the present invention as well as mixtures thereof.
  • salts of the compounds of formula 1 where a basic or acidic group is present in the structure, are also included within the scope of this invention.
  • an acidic substituent such as -COOH, 5-tetrazolyl or - P(O)(OH) 2 ⁇ there can be formed the ammonium, morpholinium, sodium, potassium, barium, calcium salt, and the like, for use as the dosage form.
  • an acidic salt such as hydrochloride, hydrobromide, phosphate, sulfate, trifluoroacetate, trichloroa- cetate, acetate, oxalate, maleate, pyruvate, malonate, succinate, citrate, tartarate, fumarate, mandelate, benzoate, cinnamate, methanesulfonate, ethane sulfonate, pi- crate and the like, and include acids related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, S6, 2 (1977) and incorporated herein by reference, can be used as the dosage form.
  • an acidic salt such as hydrochloride, hydrobromide, phosphate, sulfate, trifluoroacetate, trichloroa- cetate, acetate, oxalate, maleate, pyruvate, malonate, succinate, citrate, tartarate, fumarate, mandelate, benzoate,
  • esters can be employed, e.g., methyl, tert-butyl, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
  • some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention.
  • therapeutically effective amount shall mean that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other.
  • A is together with the double bond in Formula 1a furo[2,3-b]pyridyl, thieno[2,3- bjpyridyl, pyrrolo[2,3-bjpyridyl, furo[2,3-c]pyridyl, thieno[2,3-c]pyridyl, pyrrolo[2,3- cjpyridyl, furo[3,2-c]pyridyl, thieno[3,2-c]pyridyl, pyrrolo[3,2-c]pyridyl, furo[3,2- djpyridyl, thieno[3,2-djpyridyl, pyrrolo[3,2-d]pyridyl, furo[2,3-djpyrimidyl, thieno[2,3- djpyrimidyl, pyrrolo[2,3-d]pyrimidyl, furo[2,3-bjpyrazinyl,
  • R 12 , R 13 , and R 14 are independently hydrogen, C 1 -C ⁇ al yl l aryl, arylC C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C,- C ⁇ alkyl, aryl, arylC ⁇ Cg-alkyl, hydroxy, carboxy, carboxyC Cgalkyl, C ⁇ Cgalkyloxy- carbonyl, aryloxycarbonyi, arylC r C 6 alkyloxycarbonyl, C 1 -C 6 alkyloxy, C r C 6 alkyl- oxyC C 6 alkyl, aryloxy, arylC ⁇ Cgalkyloxy, arylC 1 -C 6 alkyl-oxyC 1 -C 6 alkyl, thio, C r
  • R 12 , R 13 , and R 14 are independently hydrogen, C C 6 alkyl, aryl, arylC 1 -C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 4 is hydrogen, hydroxy, C r C 6 alkyl, aryl, arylC r C 6 alkyl, NR 7 R 8 , C ⁇ Cgalkyloxy; wherein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C r C 6 alkyl, aryl, arylC 1 -C 6 alkyl, CF 3 , NR 7 R 8 ; wherein the alkyl and aryl groups are optionally substituted;
  • R 6 is hydrogen, C r C 6 alkyl, aryl, arylC Cgalkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, C C 6 alkyl, aryl, arylC C 6 alkyl, C 1 -C 6 alkyl-carbonyl, arylcarbonyl, arylC r C 6 alkyl-carbonyl, C r C 6 alkyl-carboxy or a- rylC 1 -C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R 7 and R 8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C C 6 alkyl, aryl, arylC 1 -C 6 alkyl, hydroxy, C ⁇ Cgalkyloxy, arylC 1 -C 6 alkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl,
  • R 7 and R 8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine or lactam;
  • A is together with the double bond in Formula 1c quinolizinyl, quinolinyl, iso- quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1 ,8-naphthyridinyl, chromanyl, thiochromanyl, isochromanyl or isothiochromanyl;
  • R 12 , R 13 , and R 14 are independently hydrogen, C Cgalkyl, aryl, arylC r C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 2 is COR 5 , OR 6 , CF 3 , nitro, cyano, SO 3 H, SO 2 NR 7 R 8 , PO(OH) 2 , CH 2 PO(OH) 2 ,
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C C 6 alkyl, aryl, arylC 1 -Cg-alkyl, hydroxy, carboxy, carboxyC r C 6 alkyl, C ⁇ Cgalkyloxy- carbonyl, aryloxycarbonyi, arylC ⁇ Cgalkyloxycarbonyl, C r C 6 alkyloxy, C C 6 alkyl- oxyC r C 6 alkyl, aryloxy, arylC 1 -C 6 alkyloxy, arylC ⁇ -Cgalkyl-oxyCrCgalkyl, thio, C r C 6 alkylthio, C CgalkylthioC Cgalkyl, arylthio, arylC 1 -C 6 alkylthio, arylC r C 6 alkylthioC r C 6 alkyl, NR 7 R 8 , C 1
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC r C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 4 is hydrogen, hydroxy, C r C 6 alkyl, aryl, arylC r C 6 alkyl, NR 7 R 8 , C r C 6 alkyloxy; whe- rein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C Cgalkyl, aryl, arylC ⁇ Cgalkyl, CF 3 , NR 7 R 8 ; wherein the alkyl and aryl groups are optionally substituted;
  • R 6 is hydrogen, C r C 6 alkyl, aryl, arylC r C 6 alkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, C r C 6 alkyl, aryl, arylC C 6 alkyl, C ⁇ Cgalkyl-carbonyl, arylcarbonyl, arylC 1 -C 6 alkyl-carbonyl, C 1 -C 6 alkyl-carboxy or a- rylC 1 -C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R 7 and R 8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one CrCgalkyl, aryl, arylC Cgalkyl, hydroxy, C C 6 alkyloxy, arylC r C 6 alkyloxy, CrCgalkyloxyC T Cgalkyl, NR 9 R 10 or C 1 -C 6
  • HN' y ⁇ ti 41 or R. is o R.
  • R 12 , R 13 , and R 14 are independently hydrogen, C C 6 alkyl, aryl, arylC r C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 3 R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C r C 6 alkyl, aryl, arylC 1 -C 6 -alkyl, hydroxy, carboxy, carboxyC r C 6 alkyl, C,-Cgalkyloxy- carbonyl, aryloxycarbonyi, arylC ⁇ Cgalkyloxycarbonyl, C C 6 alkyloxy, C ⁇ Cgalkyl- oxyC 1 -C 6 alkyl, aryloxy, arylC C 6 alkyloxy, arylC ⁇ Cgalkyl-oxyC Cgalkyl, thio, C,- C 6 alkylthio, C CgalkylthioC.-Cgalkyl, arylthio, arylC r C 6 alkylthio, arylC 1 -C 6 alkylthioC 1 - CgalkyI, NR 7 R 8 , C 1 -C 6 al
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, a ⁇ ylC C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 4 is hydrogen, hydroxy, C r C 6 alkyl, aryl, arylC r C 6 alkyl, NR 7 R 8 , C r C 6 alkyloxy; whe- rein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C r C 6 alkyl, aryl, arylC C 6 alkyl, CF 3 , NR 7 R 8 ; wherein the alkyl and aryl groups are optionally substituted;
  • R 6 is hydrogen, C Cgalkyl, aryl, arylC 1 -C 6 alkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, CrCgalkyl, aryl, arylC r C 6 alkyl, C 1 -C 6 alkyl-carbonyl, arylcarbonyl, arylC 1 -C 6 alkylcarbonyl, C C ⁇ alkyl-carboxy or a- rylC 1 -C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or
  • R 7 and R 8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C r C 6 alkyl, aryl, arylC 1 -C 6 alkyl, hydroxy, C C 6 alkyloxy, arylC,-C 6 alkyloxy, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, NR 9 R 10 or C 1 -C 6 alkylamino-C 1 -C 6 alkyl, wherein R 9 and R 10 are independently selected from hydrogen, C C 6 alkyl, aryl, a- 43 rylC r C 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylC C 6 alkylcarbonyl, C r Cgalkyl- carboxy or arylC C 6
  • R 7 and R 8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine or lactam;
  • any optical iso- mer or mixture of optical isomers including a racemic mixture, or any tautomeric forms.
  • preferred compounds of the invention are compounds of formula la, Ic or Id wherein R 16 and R 17 are hydrogen.
  • R- is o R.
  • R 12 , R 13 , and R 14 are independently hydrogen, C 1 -C ⁇ alkyl, aryl, arylC 1 -C 6 alkyl and the alkyl and aryl groups are optionally substituted;
  • R 3 , R 16 and R 17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, C C 6 alkyl, aryl, arylC r C 6 alkyl, hydroxy, oxo, carboxy, carboxyC 1 -C 6 alkyl, C,- Cgalkyloxycarbonyl, aryloxycarbonyi, aryl ⁇ -Cgalkyloxycarbonyl, C ⁇ Cgalkyloxy, C CgalkyloxyC ⁇ Cgalkyl, aryloxy, arylC 1 -C 6 alkyloxy, arylC 1 -C 6 alkyloxyC 1 -C 6 alkyl, thio, C,- C 6 alkylthio, C C 6 alkylthioC r C 6 alkyl, arylthio, arylC r C 6 alkylthio, arylC CgalkylthioC C 6 alkyl, NR 7 R 8 , C Cgalkylamin
  • R 12 , R 13 , and R 14 are independently hydrogen, C r C 6 alkyl, aryl, arylC 1 -C 6 alkyl and the alkyl and aryl groups are optionally substituted; 46
  • R 4 is hydrogen, hydroxy, C r C 6 alkyl, aryl, arylC r C 6 alkyl, NR 7 R 8 , C 1 -C 6 alkyloxy; wherein the alkyl and aryl groups are optionally substituted;
  • R 5 is hydroxy, C C ⁇ alkyl, aryl, arylC r C 6 alkyl, C r C 6 alkyloxy, C r C 6 alkyl-oxyC r
  • R 6 is hydrogen, C,-C ⁇ alkyl, aryl, arylC 1 -C 6 alkyl; wherein the alkyl and aryl groups are optionally substituted;
  • R 7 and R 8 are independently selected from hydrogen, C 1 -C 6 alkyl, aryl, arylC 1 -C 6 alkyl, C r C 6 alkylcarbonyl, arylcarbonyl, arylC r C 6 alkylcarbonyl, C r C 6 alkylcarboxy or arylC,- C 6 alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R 7 and R 8 are together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing from 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C r C ⁇ alkyl, aryl, arylC C 6 alkyl, hydroxy, oxo, C 1 -C 6 alkyloxy, arylC 1 -C 6 alkyloxy,
  • Particular preferred compounds of the invention are those compounds of formula I wherein R is 5-tetrazolyl, i.e.
  • R 5 is OH and R 4 is hydrogen.
  • the compounds are evaluated for biological activity with a truncated form of PTP1B (corresponding to the first 321 amino acids), which is expressed in E. coli and purified to apparent homogeneity using published procedures well-known to those skilled in the art.
  • the enzyme reactions are carried out using standard conditions essentially as described by Burke et al. (Biochemistry 35; 15989-15996 (1996)).
  • the assay conditions are as follows. Appropriate concentrations of the compounds of the invention are added to the reaction mixtures containing different concentrations of the substrate, p-nitrophenyl phosphate (range: 0.16 to 10 mM - final assay concentration).
  • the buffer used is 100 mM sodium acetate pH 5.5, 50 mM sodium chloride, 0.1 % (w/v) bovine serum albumin and 5 mM dithiothreitol (total volume 100 ml).
  • the reaction is started by addition of the enzyme and carried out in microtiter plates at 25° C for 60 minutes. The reactions are stopped by addition of NaOH.
  • the enzyme activity is determined by measurement of the absorbance at 405 nm with appropriate cor- reetions for absorbance at 405 nm of the compounds and p-nitrophenyl phosphate.
  • the data are analyzed using nonlinear regression fit to classical Michaelis Menten enzyme kinetic models. Inhibition is expressed as K, values in ⁇ M.
  • Table 1 The results of representative experiments are shown in Table 1
  • Example no. K values ( ⁇ M) 1 330 49
  • the compounds are evaluated for biological activity as regards their effect as inhibitors of PTP ⁇ in essentially the same way as described for inhibition of PTP1 B. Derived from their activity as evaluated above the compounds of the invention may be useful in the treatment of diseases selected from the group consisting of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance and obesity.
  • the compounds of the invention may be useful in the treatment of diseases selected from the group consisting of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferati- ve disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
  • diseases selected from the group consisting of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferati- ve disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
  • the compounds of the invention are prepared as illustrated in the following reaction scheme:
  • R 12 , R 13 , R 14 , and R 15 are independently selected from the group consisting of hydrogen, C r C 6 alkyl, aryl, arylC Cgalkyl as defined above and the alkyl and aryl groups are optionally substituted as defined above; or R 12 , R 13 , R 14 , and R 15 are independently selected from
  • Y indicates attachment point for R 12 , R 13 , R 14 , and R 15 and A, R, R 2 and R 4 are defined as above.
  • the above described four component Ugi reaction can be carried out by attaching any one of the components to a solid support. Hence, the synthesis can be accomplished in a combinatorial chemistry fashion.
  • the present invention also has the objective of providing suitable topical, oral, and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
  • the compounds of the present invention may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs.
  • the composition for oral use may contain one or more agents selected from the group of sweetening agents, flavoring agents, coloring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations.
  • the tablets contain the acting ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents such as corn starch or alginic acid
  • binding agents such as starch, gelatin or acacia
  • lubricating agents such as magnesium stearate, stearic acid or talc.
  • These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as gly
  • Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension.
  • expicients may be (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hy- droxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth 52 and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylen- oxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or (e)
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • a non-toxic parenterally-acceptable diluent or solvent for example, as a solution in 1 ,3-butanediol.
  • the acceptable vehi- cles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the Compounds of the invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
  • the compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidyl-cholines.
  • phospholipids such as cholesterol, stearylamine, or phosphatidyl-cholines.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula 1 are employed.
  • Dosage levels of the compounds of the present invention are of the order of about 0.5 mg to about 100 mg per kilogram body weight, with a preferred dosage range between about 20 mg to about 50 mg per kilogram body weight per day (from about 25 mg to about 5 g's per patient per day).
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for oral administration to humans may contain 5 mg to 1 g of an active compound with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 5 mg to about 500 mg of active ingredient.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • the dosage needs to be individualized by the clinician.
  • TLC thin layer chromatography
  • CDCI 3 deuterio chloroform
  • CD 3 OD tetradeuterio methanol
  • DMSO-d 6 hexadeuterio dimethylsulfoxide.
  • the structures of the compounds are confirmed by either elemental analysis or NMR, where peaks assigned to characteristic protons in the title compounds are presented where appropriate.
  • 1 H NMR shifts ( ⁇ H ) are given in parts per million (ppm) downfield from tetramethylsilane as internal reference standard.
  • M.p. is melting point and is given in °C and is not corrected.
  • Column chromatography is carried out using the 54 technique described by W.C. Still et al., J. Org. Chem.
  • the organic phase was washed with water (200 ml), brine (100 ml), dried (Na 2 SO 4 ), filtered and the organic phase evaporated in vacuo.
  • the residue was filtered through a path of silicagel using a mixture of 57 ethyl acetate and heptane (1 :1) as eluent.
  • the solvent was evaporated in vacuo and the residue was subjected to flash column chromatography (1 I silicagel) using ethyl acetate/hexanes (1 :2) as eluent.

Abstract

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Description

Modulators of Protein Tyrosine Phosphatases (PTPases)
FIELD OF THE INVENTION
The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1 B, CD45, SHP-1 , SHP-2, PTPα, LAR and HePTP or the like,
%17
R 1<6 w N y R2
Formula 1
wherein A, Ft,, R2, R3, R4, R16 and R17 are defined more fully below.
It has been found that PTPases plays a major role in the intracellular modulation and regulation of fundamental cellular signalling mechanisms involved in metabolism, growth, proliferation and differentiation (Flint et al., The EMBO J. 12:1937-46 (1993); Fischer et al, Science 253:401-6 (1991)). Overexpression or altered activity of tyrosi- ne phosphatases can also contribute to the symptoms and progression of various diseases (Wiener, et al., J. Natl. cancer Inst. 86:372-8 (1994); Hunter and Cooper, Ann. Rev. Biochem, 54:897-930 (1985)). Furthermore, there is increasing evidence which suggests that inhibition of these PTPases may help treat certain types of diseases such as diabetes type I and II, autoimmune disease, acute and chronic inflam- mation, osteoporosis and various forms of cancer. 2 BACKGROUND OF THE INVENTION
Protein phosphorylation is now well recognized as an important mechanism utilized by cells to transduce signals during different stages of cellular function (Fischer et al, Science 253:401-6 (1991); Flint et al., The EMBO J. 12:1937-46 (1993)). There are at least two major classes of phosphatases: (1) those that dephosphorylate proteins (or peptides) that contain a phosphate group(s) on a serine or threonine moiety (termed Ser/Thr phosphatases) and (2) those that remove a phosphate group(s) from the amino acid tyrosine (termed protein tyrosine phosphatases or PTPases).
The PTPases are a family of enzymes that can be classified into two groups: a) intracellular or nontransmembrane PTPases and b) receptor-type or transmembrane PTPases.
Intracellular PTPases: Most known intracellular type PTPases contain a single conserved catalytic phosphatase domain consisting of 220-240 amino acid residues. The regions outside the PTPase domains are believed to play important roles in localizing the intracellular PTPases subcellularly (Mauro, L.J. and Dixon, J.E. TIBS 19: 151-155 (1994)). The first intracellular PTPase to be purified and characterized was PTP1B which was isolated from human placenta (Tonks et al., J. Biol. Chem. 263: 6722-6730 (1988)). Shortly after, PTP1B was cloned (Charbonneau et al., Proc. Natl. Aead. Sci. USA 86: 5252-5256 (1989); Chemoff et al., Proc. Natl. Aead. Sci. USA 87: 2735-2789 (1989)). Other examples of intracellular PTPases include (1) T-cell PTPase (Cool et al. Proc. Natl. Aead. Sci. USA 86: 5257-5261 (1989)), (2) rat brain PTPase (Guan et al., Proc. Natl. Aead. Sci. USA 87:1501-1502 (1990)), (3) neuronal phosphatase STEP (Lombroso et al., Proc. Natl. Aead. Sci. USA 88: 7242-7246 (1991)), (4) ezrin-domain containing PTPases: PTPMEG1 (Guef al., Proc. Natl. Aead. Sci. USA 88: 5867- 57871 (1991)), PTPH1 (Yang and Tonks, Proc. Natl. Aead. Sci. USA 88: 5949- 5953 (1991)), PTPD1 and PTPD2 (Møller et al., Proc. Natl. Aead. Sci. USA 91: 7477-7481 (1994)), FAP-1/BAS (Sato et al., Science 268: 411-415 (1995); Banville et al., J. Biol. Chem. 269: 22320-22327 (1994); Maekawa et al., FEBS Letters 337: 200-206 (1994)), and SH2 domain containing PTPases: PTP1C/SH- PTP1/SHP-1 (Plutzky et al., Proc. Natl. Aead. Sci. USA 89: 1123-1127 (1992); Shen etal., Nature Lond. 352: 736-739 (1991)) and PTP1D/Syp/SH-PTP2/SHP-2 (Vogel et al., Science 259: 1611-1614 (1993); Feng et ai, Science 259: 1607- 1611 (1993); Bastein et al., Biochem. Biophys. Res. Comm. 196: 124-133 (1993)).
Low molecular weight phosphotyrosine-protein phosphatase (LMW-PTPase) shows very little sequence identity to the intracellular PTPases described above. However, this enzyme belongs to the PTPase family due to the following characteristics: (i) it possesses the PTPase active site motif: Cys-Xxx-Xxx-Xxx- Xxx-Xxx-Arg (Cirri et al., Eur. J. Biochem. 214: 647-657 (1993)); (ii) this Cys residue forms a phospho-intermediate during the catalytic reaction similar to the situation with 'classical' PTPases (Cirri et al., supra; Chiarugi et al., FEBS Lett. 310: 9-12 (1992)); (iii) the overall folding of the molecule shows a surprising degree of similarity to that of PTP1 B and Yersinia PTP (Su et al., Nature 370: 575- 578 (1994)).
Receptor-type PTPases consist of a) a putative ligand-binding extracellular domain, b) a transmembrane segment, and c) an intracellular catalytic region. The structures and sizes of the putative ligand-binding extracellular domains of receptor-type PTPases are quite divergent. In contrast, the intracellular catalytic regions of receptor-type PTPases are very homologous to each other and to the intracellular PTPases. Most receptor-type PTPases have two tandemly duplicated catalytic PTPase domains.
The first receptor-type PTPases to be identified were (1) CD45/LCA (Ralph, S.J., EMBO J. 6: 1251-1257 (1987)) and (2) LAR (Streuli et al., J. Exp. Med. 168: 1523-1530 (1988)) that were recognized to belong to this class of enzymes based on homology to PTP1B (Charbonneau et al., Proc. Natl. Aead. Sci. USA 86: 5252- 5256 (1989)). CD45 is a family of high molecular weight glycoproteins and is one 4 of the most abundant leukocyte cell surface glycoproteins and appears to be exclusively expressed upon cells of the hematopoietic system (Trowbridge and Thomas, Ann. Rev. Immunol. 12: 85-116 (1994)).
The identification of CD45 and LAR as members of the PTPase family was quickly followed by identification and cloning of several different members of the receptor- type PTPase group. Thus, 5 different PTPases, (3) PTPα, (4) PTPβ, (5) PTPδ, (6) PTPε, and (7) PTPζ, were identified in one early study (Krueger et al., EMBO J. 9: 3241-3252 (1990)). Other examples of receptor-type PTPases include (8) PTPγ (Barnea et al., Mol. Cell. Biol. 13: 1497-1506 (1995)) which, like PTPζ (Krueger and Saito, Proc. Natl. Aead. Sci. USA 89: 7417-7421 (1992)) contains a carbonic anhydrase-like domain in the extracellular region, (9) PTPμ (Gebbink et al., FEBS Letters 290: 123-130 (1991)), (10) PTPK (Jiang et al., Mol. Cell. Biol. 13: 2942- 2951 (1993)). Based on structural differences the receptor-type PTPases may be classified into subtypes (Fischer et al., Science 253: 401-406 (1991)): (I) CD45; (II) LAR, PTPd, (11) PTPσ ; (III) PTPb, (12) SAP-1 (Matozaki et al., J. Biol. Chem. 269: 2075-2081 (1994)), (13) PTP-U2/GLEPP1 (Seimiya etal., Oncogene 10: 1731-1738 (1995); Thomas et al., J. Biol. Chem. 269: 19953-19962 (1994)), and (14) DEP-1; (IV) PTPa,_PTPe. All receptor-type PTPases except Type IV contain two PTPase domains. Novel PTPases are continuously identified, and it is anticipated that more than 500 different species will be found in the human genome, i.e. close to the predicted size of the protein tyrosine kinase superfamily (Hanks and Hunter, FASEB J. 9: 576-596 (1995)).
PTPases are the biological counterparts to protein tyrosine kinases (PTKs). Therefore, one important function of PTPases is to control, down-regulate, the activity of PTKs. However, a more complex picture of the function of PTPases now emerges. Several studies have shown that some PTPases may actually act as positive mediators of cellular signalling. As an example, the SH2 domain- containing PTP1 D seems to act as a positive mediator in insulin-stimulated Ras activation (Noguchi et al., Mol. Cell. Biol. 14: 6674-6682 (1994)) and of growth 5 factor-induced mitogenic signal transduction (Xiao et al., J. Biol. Chem. 269: 21244-21248 (1994)), whereas the homologous PTP1C seems to act as a negative regulator of growth factor-stimulated proliferation (Bignon and Siminovitch, Clin. Immunol. Immunopathol. 73: 168-179 (1994)). Another example of PTPases as positive regulators has been provided by studies designed to define the activation of the Src-family of tyrosine kinases. In particular, several lines of evidence indicate that CD45 is positively regulating the activation of hematopoietic cells, possibly through dephosphorylation of the C-terminal tyrosine of Fyn and Lck (Chan et al., Annu. Rev. Immunol. 12: 555-592 (1994)).
Dual specificity protein tyrosine phosphatases (dsPTPases) define a subclass within the PTPases family that can hydrolyze phosphate from phosphortyrosine as well as from phosphor-serine/threonine. dsPTPases contain the signature sequence of PTPases: His-Cys-Xxx-Xxx-Gly-Xxx-Xxx-Arg. At least three dsPTPases have been shown to dephosphorylate and inactivate extracellular signal-regulated kinase (ERKs)/mitogen-activated protein kinase (MAPK): MAPK phosphatase (CL100, 3CH134) (Charles et al., Proc. Natl. Aead. Sci. USA 90: 5292-5296 (1993)); PAC-1 (Ward et al., Nature 367: 651-654 (1994)); rVH6 (Mourey et al., J. Biol. Chem. 271: 3795-3802 (1996)). Transcription of dsPTPases are induced by different stimuli, e.g. oxidative stress or heat shock (Ishibashi et ai, J. Biol. Chem. 269: 29897-29902 (1994); Keyse and Emslie, Nature 359: 644-647 (1992)). Further, they may be involved in regulation of the cell cycle: cdc25 (Millar and Russell, Cell 68: 407-410 (1992)); KAP (Hannon et al., Proc. Natl. Aead. Sci. USA 91: 1731-1735 (1994)). Interestingly, tyrosine dephosphorylation of cdc2 by a dual specific phosphatase, cdc25, is required for induction of mitosis in yeast (review by Walton and Dixon, Annu. Rev. Biochem. 62: 101-120 (1993)).
PTPases were originally identified and purified from cell and tissue lysates using a variety of artificial substrates and therefore their natural function of dephosphorylati- on was not well known. Since tyrosine phosphorylation by tyrosine kinases is usually 6 associated with cell proliferation, cell transformation and cell differentiation, it was assumed that PTPases were also associated with these events. This association has now been proven to be the case with many PTPases. PTP1B, a phosphatase whose structure was recently elucidated (Barford et al., Science 263:1397-1404 (1994)) has been shown to be involved in insulin-induced oocyte maturation (Flint et al., The EMBO J. 12:1937-46 (1993)) and recently it has been c-er B2 suggested that the overexpression of this enzyme may be involved in p185 associated breast and ovarian cancers (Wiener, et al., J. Natl. cancer Inst. 86:372-8 (1994); Weiner et al., Am. J. Obstet. Gynecol. 170:1177-883 (1994)). The insulin- induced oocyte maturation mechanism has been correlated with the ability of PTP1 B to block activation of S6 kinase. The association with cancer is recent evidence which suggests that overexpression of PTP1B is statistically correlated with increased levels of pISS0* 2 in ovarian and breast cancer. The role of PTP1B in the etiology and progression of the disease has not yet been elucidated. Inhibitors of PTP1 B may therefore help clarify the role of PTP1 B in cancer and in some cases provide therapeutic treatment for certain forms of cancer.
The activity of a number of other newly discussed phosphatases are currently under investigation. Two of these: SHP-1 and Syp/PTP1 D/SHPTP2/PTP2C/SHP-2 have recently been implicated in the activation of Platelet Derived Growth Factor and Epidermal Growth Factor induced responses (Li et al., Mole. Cell. Biol. 14:509-17 (1994)). Since both growth factors are involved in normal cell processing as well as disease states such as cancer and arteriosclerosis, it is hypothesized that inhibitors of these phosphatases would also show therapeutic efficacy. Accordingly, the com- pounds of the present invention which exhibit inhibitory activity against various PTPases, are indicated in the treatment or management of the foregoing diseases.
PTPases: the insulin receptor signalling pathway/diabetes
Insulin is an important regulator of different metabolic processes and plays a key role in the control of blood glucose. Defects related to its synthesis or signalling 7 lead to diabetes mellitus. Binding of insulin to its receptor causes rapid (auto)phosphorylation of several tyrosine residues in the intracellular part of the b- subunit. Three closely positioned tyrosine residues (the tyrosine-1150 domain) must all be phosphorylated to obtain full activity of the insulin receptor tyrosine kinase (IRTK) which transmits the signal further downstream by tyrosine phosphorylation of other cellular substrates, including insulin receptor substrate-1 (IRS-1) (Wilden et al., J. Biol. Chem. 267: 16660-16668 (1992); Myers and White, Diabetes 42: 643-650 (1993); Lee and Pilch, Am. J. Physiol. 266: C319-C334 (1994); White et al., J. Biol. Chem. 263: 2969-2980 (1988)). The structural basis for the function of the tyrosine-triplet has been provided by recent X-ray crystallographic studies of IRTK that showed tyrosine-1150 to be autoinhibitory in its unphosphorylated state (Hubbard et al., Nature 372: 746-754 (1994)).
Several studies clearly indicate that the activity of the auto-phosphorylated IRTK can be reversed by dephosphorylation in vitro (reviewed in Goldstein, Receptor 3: 1-15 (1993); Mooney and Anderson, J. Biol. Chem. 264: 6850-6857 (1989)), with the tri-phosphorylated tyrosine-1150 domain being the most sensitive target for protein-tyrosine phosphatases (PTPases) as compared to the di- and mono- phosphorylated forms (King etal., Biochem. J. 275: 413-418 (1991)). It is, therefore, tempting to speculate that this tyrosine-triplet functions as a control switch of IRTK activity. Indeed, the IRTK appears to be tightly regulated by PTP- mediated dephosphorylation in vivo (Khan et al., J. Biol. Chem. 264: 12931-12940 (1989); Faure et al., J. Biol. Chem. 267: 11215-11221 (1992); Rothenberg et al., J. Biol. Chem. 266: 8302-8311 (1991)). The intimate coupling of PTPases to the insulin signalling pathway is further evidenced by the finding that insulin differentially regulates PTPase activity in rat hepatoma cells (Meyerovitch et al., Biochemistry 31: 10338-10344 (1992)) and in livers from alloxan diabetic rats (Boylan et al., J. Clin. Invest. 90: 174-179 (1992)).
Relatively little is known about the identity of the PTPases involved in IRTK regulation. However, the existence of PTPases with activity towards the insulin 8 receptor can be demonstrated as indicated above. Further, when the strong PTPase-inhibitor pervanadate is added to whole cells an almost full insulin response can be obtained in adipocytes (Fantus et al., Biochemistry 28: 8864- 8871 (1989); Eriksson et al., Diabetologia 39: 235-242 (1995)) and skeletal muscle (Leighton et al., Biochem. J. 276: 289-292 (1991)). In addition, recent studies show that a new class of peroxovanadium compounds act as potent hypoglycemic compounds in vivo (Posner et al., supra). Two of these compounds were demonstrated to be more potent inhibitors of dephosphorylation of the insulin receptor than of the EGF-receptor.
It was recently found that the ubiquitously expressed SH2 domain containing PTPase, PTP1D (Vogel etal., 1993, supra), associates with and dephosphorylates IRS-1 , ut apparently not the IR itself (Kuhne et al., J. Biol. Chem. 268: 11479-11481 (1993); (Kuhne etal., J. Biol. Chem. 269: 15833-15837 (1994)).
Previous studies suggest that the PTPases responsible for IRTK regulation belong to the class of membrane-associated (Faure et al., J. Biol. Chem. 267: 11215- 11221 (1992)) and glycosylated molecules (Haring et al., Biochemistry 23: 3298- 3306 (1984); Sale, Adv. Prot. Phosphatases 6: 159-186 (1991)). Hashimoto et al. have proposed that LAR might play a role in the physiological regulation of insulin receptors in intact cells (Hashimoto et al., J. Biol. Chem. 267: 13811-13814 (1992)). Their conclusion was reached by comparing the rate of dephosphoryl- ation/inactivation of purified IR using recombinant PTP1B as well as the cytoplasmic domains of LAR and PTPa. Antisense inhibition was recently used to study the effect of LAR on insulin signalling in a rat hepatoma cell line (Kulas et al., J. Biol. Chem. 270: 2435-2438 (1995)). A suppression of LAR protein levels by about 60 percent was paralleled by an approximately 150 percent increase in insulin-induced auto-phosphorylation. However, only a modest 35 percent increase in IRTK activity was observed, whereas the insulin-dependent phosphatidylinositol 3-kinase (PI 3-kinase) activity was significantly increased by 350 percent. Reduced LAR levels did not alter the basal level of IRTK tyrosine 9 phosphorylation or activity. The authors speculate that LAR could specifically dephosphorylate tyrosine residues that are critical for PI 3-kinase activation either on the insulin receptor itself or on a downstream substrate.
While previous reports indicate a role of PTPa in signal transduction through src activation (Zheng et ai, Nature 359: 336-339 (1992); den Hertog et al., EMBO J. 12: 3789-3798 (1993)) and interaction with GRB-2 (den Hertog et al., EMBO J. 13: 3020-3032 (1994); Su et al., J. Biol. Chem. 269: 18731-18734 (1994)), a recent study suggests a function for this phosphatase and its close relative PTPe as negative regulators of the insulin receptor signal (Møller et ai, 1995 supra). This study also indicates that receptor-like PTPases play a significant role in regulating the IRTK, whereas intracellular PTPases seem to have little, if any, activity towards the insulin receptor. While it appears that the target of the negative^ regulatory activity of PTPases a and e is the receptor itself, the downmodulating effect of the intracellular TC-PTP seems to be due to a downstream function in the IR-activated signal. Although PTP1B and TC-PTP are closely related, PTP1B had only little influence on the phosphorylation pattern of insulin-treated cells. Both PTPases have distinct structural features that determine their subcellular localization and thereby their access to defined cellular substrates (Frangione et ai, Cell 68: 545-560 (1992); Faure and Posner, Glia 9: 311-314 (1993)).
Therefore, the lack of activity of PTP1 B and TC-PTP towards the IRTK may, at least in part, be explained by the fact that they do not co-localize with the activated insulin receptor. In support of this view, PTP1B and TC-PTP have been excluded as candidates for the IR-associated PTPases in hepatocytes based on subcellular localization studies (Faure et ai, J. Biol. Chem. 267: 11215-11221 (1992)).
The transmembrane PTPase CD45, which is believed to be hematopoietic cell- specific, was in a recent study found to negatively regulate the insulin receptor tyrosine kinase in the human multiple myeloma cell line U266 (Kulas et ai, J. Biol. Chem. 271: 755-760 (1996)). 10
PTPases: somatostatin
Somatostatin inhibits several biological functions including cellular proliferation (Lamberts et al., Molec. Endocrinoi 8: 1289-1297 (1994)). While part of the antiproliferative activities of somatostatin are secondary to its inhibition of hormone and growth factor secretion (e.g. growth hormone and epidermal growth factor), other antiproliferative effects of somatostatin are due to a direct effect on the target cells. As an example, somatostatin analogs inhibit the growth of pancreatic cancer presumably via stimulation of a single PTPase, or a subset of PTPases, rather than a general activation of PTPase levels in the cells (Liebow et ai, Proc. Natl. Aead. Sci. USA 86: 2003-2007 (1989); Colas et ai, Eur. J. Biochem. 207: 1017-1024 (1992)). In a recent study it was found that somatostatin stimulation of somatostatin receptors SSTR1, but not SSTR2, stably expressed in CHO-K1 cells can stimulate PTPase activity and that this stimulation is pertussis toxin-sensitive. Whether the inhibitory effect of somatostatin on hormone and growth factor secretion is caused by a similar stimulation of PTPase activity in hormone producing cells remains to be determined.
PTPases: the immune system/autoimmunity
Several studies suggest that the receptor-type PTPase CD45 plays a critical role not only for initiation of T cell activation, but also for maintaining the T cell receptor- mediated signalling cascade. These studies are reviewed in: (Weiss A., Ann. Rev. Genet. 25: 487-510 (1991); Chan et ai, Annu. Rev. Immunol. 12: 555-592 (1994); Trowbridge and Thomas, Annu. Rev. Immunol. 12: 85-116 (1994)).
CD45 is one of the most abundant of the cell surface glycoproteins and is expressed exclusively on hemopoetic cells. In T cells, it has been shown that CD45 is one of the critical components of the signal transduction machinery of lymphocytes. In particular, evidence has suggested that CD45 phosphatase plays a pivotal role in antigen- stimulated proliferation of T lymphocytes after an antigen has bound to the T cell receptor (Trowbridge, Ann. Rev. Immunol, 12:85-116 (1994)). Several studies suggest 11 that the PTPase activity of CD45 plays a role in the activation of Lck, a lymphocyte- specific member of the Src family protein-tyrosine kinase (Mustelin etal., Proc. Natl. Aead. Sci. USA 86: 6302-6306 (1989); Ostergaard et al., Proc. Natl. Aead. Sci. USA 86: 8959-8963 (1989)). These authors hypothesized that the phosphatase activity of CD45 activates Lck by dephosphorylation of a C-terminal tyrosine residue, which may, in turn, be related to T-cell activation. In a recent study it was found that recombinant p56lck specifically associates with recombinant CD45 cytoplasmic domain protein, but not to the cytoplasmic domain of the related PTPa (Ng et al., J. Biol. Chem. 271: 1295-1300 (1996)). The p56lck-CD45 interaction seems to be mediated via a nonconventional SH2 domain interaction not requiring phosphotyrosine. In immature B cells, another member of the Src family protein-tyrosine kinases, Fyn, seems to be a selective substrate for CD45 compared to Lck and Syk (Katagiri et al., J. Biol. Chem. 270: 27987-27990 (1995)).
Studies using transgenic mice with a mutation for the CD45-exon6 exhibited lacked mature T cells. These mice did not respond to an antigenic challenge with the typical T cell mediated response (Kishihara et al., Cell 74:143-56 (1993)). Inhibitors of CD45 phosphatase would therefore be very effective therapeutic agents in conditions that are associated with autoimmune disease.
CD45 has also been shown to be essential for the antibody mediated degranulation of mast cells (Berger et al., J. Exp. Med. 180:471-6 (1994)). These studies were also done with mice that were CD45-defιcient. In this case, an IgE-mediated degranulation was demonstrated in wild type but not CD45-deficient T cells from mice. These data suggest that CD45 inhibitors could also play a role in the symptomatic or therapeutic treatment of allergic disorders.
Another recently discovered PTPase, an inducible lymphoid-specific protein tyrosine phosphatase (HePTP) has also been implicated in the immune response. This phos- phatase is expressed in both resting T and B lymphocytes, but not non-hemopoetic cells. Upon stimulation of these cells, mRNA levels from the HePTP gene increase 10-15 fold (Zanke et al., Eur. J. Immunol. 22:235-239 (1992)). In both T and B cells 12
HePTP may function during sustained stimulation to modulate the immune response through dephosphorylation of specific residues. Its exact role, however remains to be defined.
Likewise, the hematopoietic cell specific PTP1 C seems to act as a negative regulator and play an essential role in immune cell development. In accordance with the above-mentioned important function of CD45, HePTP and PTP1C, selective PTPase inhibitors may be attractive drug candidates both as immunosuppressors and as immunostimulants. One recent study illustrates the potential of PTPase inhibitors as immunmodulators by demonstrating the capacity of the vanadium-based PTPase inhibitor, BMLOV, to induce apparent B cell selective apoptosis compared to T cells (Schieven et al., J. Biol. Chem. 270: 20824-20831 (1995)).
PTPases: cell-cell interactions/cancer
Focal adhesion plaques, an in vitro phenomenon in which specific contact points are formed when fibroblasts grow on appropriate substrates, seem to mimic, at least in part, cells and their natural surroundings. Several focal adhesion proteins are phosphorylated on tyrosine residues when fibroblasts adhere to and spread on extracellular matrix (Gumbiner, Neuron 11, 551-564 (1993)). However, aberrant tyrosine phosphorylation of these proteins can lead to cellular transformation. The intimate association between PTPases and focal adhesions is supported by the finding of several intracellular PTPases with ezrin-like N-terminal domains, e.g. PTPMEG1 (Gu et ai, Proc. Natl. Aead. Sci. USA 88: 5867-5871 (1991)), PTPH1 (Yang and Tonks, Proc. Natl. Aead. Sci. USA 88: 5949-5953 (1991)) and PTPD1 (Møller et al., Proc. Natl. Aead. Sci. USA 91: 7477-7481 (1994)). The ezrin-like domain show similarity to several proteins that are believed to act as links between the cell membrane and the cytoskeleton. PTPD1 was found to be phosphorylated by and associated with c-src in vitro and is hypothesized to be involved in the regulation of phosphorylation of focal adhesions (Møller et ai, supra). 13
PTPases may oppose the action of tyrosine kinases, including those responsible for phosphorylation of focal adhesion proteins, and may therefore function as natural inhibitors of transformation. TC-PTP, and especially the truncated form of this enzyme (Cool et ai, Proc. Natl. Aead. Sci. USA 87: 7280-7284 (1990)), can inhibit the transforming activity of v-erb and v-fms (Lammers et ai, J. Biol. Chem. 268: 22456-22462 (1993); Zander et ai, Oncogene 8: 1175-1182 (1993)). Moreover, it was found that transformation by the oncogenic form of the HER2/neu gene was suppressed in NIH 3T3 fribroblasts overexpressing PTP1B (Brown- Shimer et ai, Cancer Res. 52: 478-482 (1992)).
The expression level of PTP1B was found to be increased in a mammary cell line transformed with neu (Zhay et ai, Cancer Res. 53: 2272-2278 (1993)). The intimate relationship between tyrosine kinases and PTPases in the development of cancer is further evidenced by the recent finding that PTPe is highly expressed in murine mammary tumors in transgenic mice over-expressing c-neu and v-Ha-ras, but not c-myc or int-2 (Elson and Leder, J. Biol. Chem. 270: 26116-26122 (1995)). Further, the human gene encoding PTPg was mapped to 3p21, a chromosomal region which is frequently deleted in renal and lung carcinomas (LaForgia et ai, Proc. Natl. Aead. Sci. USA 88: 5036-5040 (1991)).
In this context, it seems significant that PTPases appear to be involved in controlling the growth of fibroblasts. In a recent study it was found that Swiss 3T3 cells harvested at high density contain a membrane-associated PTPase whose activity on an average is 8-fold higher than that of cells harvested at low or medium density (Pallen and Tong, Proc. Natl. Aead. Sci. USA 88: 6996-7000 (1991)). It was hypothesized by the authors that density-dependent inhibition of cell growth involves the regulated elevation of the activity of the PTPase(s) in question. In accordance with this view, a novel membrane-bound, receptor-type PTPase, DEP-1 , showed enhanced (>=10-fold) expression levels with increasing cell density of WI-38 human embryonic lung fibroblasts and in the AG 1518 14 fibroblast cell line (Ostman et al., Proc. Natl. Aead. Sci. USA 91: 9680-9684 (1994)).
Two closely related receptor-type PTPases, PTPK and PTPμ, can mediate homophilic cell-cell interaction when expressed in non-adherent insect cells, suggesting that these PTPases might have a normal physiological function in cell- to-cell signalling (Gebbink er a/., J. Biol. Chem. 268: 16101-16104 (1993); Brady- Kalnay er /., J. Cell Biol. 122: 961-972 (1993); Sap et ai, Mol. Cell. Biol. 14: 1-9 (1994)). Interestingly, PTPk and PTPμ do not interact with each other, despite their structural similarity (Zondag et ai, J. Biol. Chem. 270: 14247-14250 (1995)). From the studies described above it is apparent that PTPases may play an important role in regulating normal cell growth. However, as pointed out above, recent studies indicate that PTPases may also function as positive mediators of intracellular signalling and thereby induce or enhance mitogenic responses. Increased activity of certain PTPases might therefore result in cellular transformation and tumor formation. Indeed, in one study over-expression of PTPα was found to lead to transformation of rat embryo fibroblasts (Zheng, supra). In addition, a novel PTP, SAP-1 , was found to be highly expressed in pancreatic and colorectal cancer cells. SAP-1 is mapped to chromosome 19 region q13.4 and might be related to carcinoembryonic antigen mapped to 19q13.2 (Uchida et ai, J. Biol. Chem. 269: 12220-12228 (1994)). Further, the dsPTPase, cdc25, dephosphorylates cdc2 at Thr14/Tyr-15 and thereby functions as positive regulator of mitosis (reviewed by Hunter, Cell 80: 225-236 (1995)). Inhibitors of specific PTPases are therefore likely to be of significant therapeutic value in the treatment of certain forms of cancer.
PTPases: platelet aggregation
Recent studies indicate that PTPases are centrally involved in platelet aggregation. Agonist-induced platelet activation results in calpain-catalyzed cleavage of PTP1 B with a concomitant 2-fold stimulation of PTPase activity 15
(Frangioni et al., EMBO J. 12: 4843-4856 (1993)). The cleavage of PTP1B leads to subcellular relocation of the enzyme and correlates with the transition from reversible to irreversible platelet aggregation in platelet-rich plasma. In addition, the SH2 domain containing PTPase, SHP-1, was found to translocate to the cytoskeleton in platelets after thrombin stimulation in an aggregation-dependent manner (Li et ai, FEBS Lett. 343: 89-93 (1994)).
Although some details in the above two studies were recently questioned there is over-all agreement that PTP1B and SHP-1 play significant functional roles in platelet aggregation (Ezumi et ai, J. Biol. Chem. 270: 11927-11934 (1995)). In accordance with these observations, treatment of platelets with the PTPase inhibitor pervanadate leads to significant increase in tyrosine phosphorylation, secretion and aggregation (Pumiglia et al., Biochem. J. 286: 441-449 (1992)).
PTPases: osteoporosis
The rate of bone formation is determined by the number and the activity of osteoblasts, which in term are determined by the rate of proliferation and differentiation of osteoblast progenitor cells, respectively. Histomorphometric studies indicate that the osteoblast number is the primary determinant of the rate of bone formation in humans (Gruber et ai, Mineral Electrolyte Metab. 12: 246-254 (1987); reviewed in Lau etal., Biochem. J. 257: 23-36 (1989)). Acid phosphatases/PTPases may be involved in negative regulation of osteoblast proliferation. Thus, fluoride, which has phosphatase inhibitory activity, has been found to increase spinal bone density in osteoporotics by increasing osteoblast proliferation (Lau ef ai, supra). Consistent with this observation, an osteoblastic acid phosphatase with PTPase activity was found to be highly sensitive to mitogenic concentrations of fluoride (Lau er a/., J. Biol. Chem. 260: 4653-4660 (1985); Lau et ai, J. Biol. Chem. 262: 1389-1397 (1987); Lau et ai, Adv. Protein Phosphatases 4: 165-198 (1987)). Interestingly, it was recently found that the level of membrane-bound PTPase activity was increased dramatically when the 16 osteoblast-like cell line UMR 106.06 was grown on collagen type-l matrix compared to uncoated tissue culture plates. Since a significant increase in PTPase activity was observed in density-dependent growth arrested fibroblasts (Pallen and Tong, Proc. Natl. Aead. Sci. 88: 6996-7000 (1991)), it might be speculated that the increased PTPase activity directly inhibits cell growth. The mitogenic action of fluoride and other phosphatase inhibitors (molybdate and vanadate) may thus be explained by their inhibition of acid phosphatases/PTPases that negatively regulate the cell proliferation of osteoblasts. The complex nature of the involvement of PTPases in bone formation is further suggested by the recent identification of a novel parathyroid regulated, receptor-like PTPase, OST-PTP, expressed in bone and testis (Mauro et ai, J. Biol. Chem. 269: 30659-30667 (1994)). OST-PTP is up-regulated following differentiation and matrix formation of primary osteoblasts and subsequently down- regulated in the osteoblasts which are actively mineralizing bone in culture. It may be hypothesized that PTPase inhibitors may prevent differentiation via inhibition of OST-PTP or other PTPases thereby leading to continued proliferation. This would be in agreement with the above-mentioned effects of fluoride and the observation that the tyrosine phosphatase inhibitor orthovanadate appears to enhance osteoblast proliferation and matrix formation (Lau et ai, Endocrinology 116: 2463- 2468 (1988)). In addition, it was recently observed that vanadate, vanadyl and pervanadate all increased the growth of the osteoblast-like cell line UMR106. Vanadyl and pervanadate were stronger stimulators of cell growth than vanadate. Only vanadate was able to regulate the cell differentiation as measured by cell alkaline phosphatase activity (Cortizo et ai, Mol. Cell. Biochem. 145: 97-102 (1995)).
PTPases: microorganisms
Dixon and coworkers have called attention to the fact that PTPases may be a key element in the pathogenic properties of Yersinia (reviewed in Clemens et al. Molecular Microbiology 5: 2617-2620 (1991)). This finding was rather surprising 17 since tyrosine phosphate is thought to be absent in bacteria. The genus Yersinia comprises 3 species: Y. pestis (responsible for the bubonic plague), Y. pseudoturberculosis and Y. enterocolitica (causing enteritis and mesenteric lymphadenitis). Interestingly, a dual-specificity phosphatase, VH1 , has been identified in Vaccinia virus (Guan et ai, Nature 350: 359-263 (1991)). These observations indicate that PTPases may play critical roles in microbial and parasitic infections, and they further point to PTPase inhibitors as a novel, putative treatment principle of infectious diseases.
SUMMARY OF THE INVENTION
The present invention relates to compounds of the general formula I, wherein A, R1 τ R2, R3, R4, R16 and R17are as defined in the detailed part of the present description, wherein such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1 , SHP-2, PTPα, LAR and HePTP or the like.
The present compounds are useful for the treatment, prevention, elimination, alleviation or amelioration of an indication related to type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
In another aspect, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent. 18
In another aspect of the present invention there is provided a method of treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
The method of treatment may be described as the treatment, prevention, elimination, alleviation or amelioration of one of the above indications, which comprises the step of administering to the said subject a neurologically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
A further aspect of the invention relates to the use of a compound of the present invention for the preparation of a pharmaceutical composition for the treatment of all type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity and AIDS, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizo- phrenia, and infectious diseases.
DESCRIPTION OF THE INVENTION
The present invention relates to Compounds of the Formula 1 wherein A, R1 ( R2, R3, R4, R16 and R17 are defined below; 19
17>
N o h*.
Formula 1 In the above Formula 1
A is together with the double bond in Formula 1 furo[2,3-b]pyridyl, thieno[2,3- bjpyridyl, pyrrolo[2,3-b]pyridyl, furo[2,3-c]pyridyl, thieno[2,3-c]pyridyl, pyrrolo[2,3- cjpyridyl, furo[3,2-c]pyridyl, thieno[3,2-c]pyridyl, pyrrolo[3,2-c]pyridyl, furo[3,2- djpyridyl, thieno[3,2-d]pyridyl, pyrrolo[3,2-d]pyridyl, furo[2,3-d]pyrimidyl, thieno[2,3- djpyrimidyl, pyrrolo[2,3-d]pyrimidyl, furo[2,3-bjpyrazinyl, thieno[2,3-b]pyrazinyl, pyr- rolo[2,3-b]pyrazinyl, furo[2,3-c]pyridazinyl, thieno[2,3-cjpyridazinyl, pyrrolo[2,3- cjpyridazinyl, furo[2,3-djpyridazinyl, thieno[2,3-d]pyridazinyl, pyrrolo[2,3-d]pyridazinyl, furo[3,2-c]pyridazinyl, thieno[3,2-c]pyridazinyl, pyrrolo[3,2-c]pyridazinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8- naphthyridinyl, chromanyl, thiochromanyl, isochromanyl, isothiochromanyl, 2,3- dihydro-thieno[2,3-b]furanyl, 4,6-dihydro-thieno[2,3-c]furanyl, 2,3-dihydro-thieno[3,2- bjfuranyl, 4,5-dihydro-thieno[2,3-b]thiophenyl, 4,6-dihydro-thieno[3,4-b]thiophenyl, 5,6-dihydro-thieno[3,2-b]thiophenyl, 4,5-dihydro-thieno[2,3-b]pyrrolyl, thieno[3,2- djisothiazolyl, thieno[3,2-d]thiazolyl, thieno[2,3-d]thiazolyl, thieno[2,3-c]pyrrolyl-4,6- dione, 1H-thieno[2,3-d]imidazolyl, 6H-thieno[2,3-b]pyrrolyl, 5,6-dihydro-4H- thieno[2,3-c]pyrrolyl or 4H-thieno[3,2-bjpyrrolyl;
R, is hydrogen, COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 or selected from the following 5-membered heterocycles: 20
H
"4.
N. N 0'V0H S' OH HN ;s
H o
N y ft.N - 'S-0 θ ) \'V =H ' OH S N ) \'NV =N ' -0H ft'VOH N'NVSH x / y \\-o '
fir mχrw )-V0H prOH fτ°
I 0I
HN s
or R1 is
0 R«
R12 O
wherein R12, R13, and R14 are independently hydrogen, CrC6alkyl, aryl, arylC C6alkyl and the alkyl and aryl groups are optionally substituted;
R2 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 , or selected from the following 5- membered heterocycles:
21
H P
N'N N θ VOH S'V°H HN' 0H HN'^o N
j — *
N ft'N S ' =0 θ \'V ' OH S \'V ' OH ft'V ' 0H N \\' _-! SH -0 )=N )=N )-0 ^O
N r0H r0H r0H (V0H t °
p
H,r%
R3, R16 and R17are independently hydrogen, halo, nitro, cyano, trihalomethyl, C,- C6alkyl, aryl, arylC C6alkyl, hydroxy, oxo, carboxy, carboxyC C6alkyl, Cr Cgalkyloxycarbonyl, aryloxycarbonyi, arylCrC6alkyloxycarbonyl, CrC6alkyloxy, Cr C6alkyloxyC,-C6alkyl, aryloxy, arylCrC6alkyloxy, arylC1-C6alkyloxyC1-C6alkyl, thio, C C6alkylthio, C1-C6alkylthioC1-C6alkyl, arylthio, arylCrC6alkylthio, arylC1-C6alkylthioC1- C6alkyl, NR7R8, C1-C6alkylaminoC1-C6alkyl, arylC CgalkylaminoC Cgalkyl, di(arylCr C6alkyl)aminoC C6alkyl, C^Cgalkylcarbonyl, C^Cgalkylcarbonyl-C^Cgalkyl, arylCr C6alkylcarbonyl, arylC1-C6alkylcarbonylC1-C6alkyl, C1-C6alkylcarboxy, C
C6alkylcarboxyC1-C6-alkyl, arylcarboxy, arylcarboxyC1-C6alkyl, arylCϊ-Cgalkylcarboxy, arylC1-C6alkylcarboxyC1-C6alkyl, C1-Cβalkyl-carbonylamino, Cr C6alkylcarbonylaminoCrC6alkyl, -carbonylNR^-CgalkylCORn, arylCr C6alkylcarbonylamino, arylC1-C6alkylcarbonyl-aminoC1-C6alkyl, CONR7R8, or C,- C6alkylCONR7R8 wherein the alkyl and aryl groups are optionally substituted and R^ is NR7R8, or C C6alkylNR7R8; or R3 is
R12 O
wherein R12, R13, and R14 are independently hydrogen, C1-C6alkyl, aryl, arylC1-C6alkyl and the alkyl and aryl groups are optionally substituted; 22
R4 is hydrogen, hydroxy, C1-C6alkyl, aryl, arylC^Cgalkyl, NR7R8, C C6alkyloxy; wherein the alkyl and aryl groups are optionally substituted;
R5 is hydroxy, C1-C6alkyl, aryl, arylC1-C6alkyl, C^Cgalkyloxy, C1-C6alkyl-oxyC1-
C6alkyloxy, aryloxy, arylC.-Cgalkyloxy, CF3, NR7R8; wherein the alkyl and aryl groups are optionally substituted;
R6 is hydrogen, C^Cgalkyl, aryl, arylC1-C6alkyl; wherein the alkyl and aryl groups are optionally substituted;
R7 and R8 are independently selected from hydrogen, C C6alkyl, aryl, arylC C6alkyl, C C6alkylcarbonyl, arylcarbonyl, arylCrC6alkylcarbonyl, CrC6alkylcarboxy or arylC C6alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing from 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C1-C6alkyl, aryl, arylC C6alkyl, hydroxy, oxo, CrC6alkyloxy, arylC C6alkyloxy, C1-C6alkyloxyC1-C6alkyl, NR9R10 or C1-C6alkylaminoC1-C6alkyl, wherein R9 and R10 are independently selected from hydrogen, C1-C6alkyl, aryl, arylCrC6alkyl, C,- C6alkylcarbonyl, arylcarbonyl, arylC1-C6alkylcarbonyl, CrC6alkylcarboxy or arylC C6alkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine, imide or lactam;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical iso- mer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms. 23 DEFINITIONS
Signal transduction is a collective term used to define all cellular processes that follow the activation of a given cell or tissue. Examples of signal transduction, which are not intended to be in any way limiting to the scope of the invention claimed, are cellular events that are induced by polypeptide hormones and growth factors (e.g. insulin, insulin-like growth factors I and II, growth hormone, epidermal growth factor, platelet-derived growth factor), cytokines (e.g. interleukins), extracellular matrix components, and cell-cell interactions.
Phosphotyrosine recognition units/tyrosine phosphate recognition units/pTyr recognition units are defined as areas or domains of proteins or gly- coproteins that have affinity for molecules containing phosphorylated tyrosine residues (pTyr). Examples of pTyr recognition units, which are not intended to be in any way limiting to the scope of the invention claimed, are: PTPases, SH2 domains and PTB domains.
PTPases are defined as enzymes with the capacity to dephosphorylate pTyr- containing proteins or glycoproteins. Examples of PTPases, which are not intended to be in any way limiting to the scope of the invention claimed, are: 'classical' PTPases (intracellular PTPases (e.g. PTP1B, TC-PTP, PTP1C, PTP1D, PTPD1 , PTPD2) and receptor-type PTPases (e.g. PTPα, PTPε, PTPβ, PTPγ, CD45, PTPK, PTPμ), dual speci- ficty phosphatases (VH1, VHR, cdc25), LMW-PTPases or acid phosphatases.
SH2 domains (Src homology 2 domains) are non-catalytic protein modules that bind to pTyr (phosphotyrosine residue) containing proteins, i.e. SH2 domains are pTyr recognition units. SH2 domains, which consist of ~100 amino acid residues, are found in a number of different molecules involved in signal transduction processes. The following is a non-limiting list of proteins containing SH2 domains: Src, Hck, Lck, Syk, Zap70, SHP-1 , SHP-2, STATs, Grb-2, She, p85/PI3K, Gap, vav (see Russell et al, FEBS Lett. 24
304:15-20 (1992); Pawson, Nature 373: 573-580 (1995); Sawyer, Biopolymers (Peptide Science) 47: 243-261 (1998); and references herein).
As used herein, the term "attached" or "-" (e.g. -COR^ which indicates the carbonyl attachment point to the scaffold) signifies a stable covalent bond, certain preferred points of attachment points being apparent to those skilled in the art. The terms "halogen" or "halo" include fluorine, chlorine, bromine, and iodine. The term "alkyl" includes CrC6 straight chain, methylene, saturated and C2-C6 unsaturated aliphatic hydrocarbon groups, CrC6 branched saturated and C2-C6 unsatu- rated aliphatic hydrocarbon groups, C3-C6 cyclic saturated and C5-C6 unsaturated aliphatic hydrocarbon groups, and CrC6 straight chain or branched saturated and C2-' C6 straight chain or branched unsaturated aliphatic hydrocarbon groups substituted with C3-C6 cyclic saturated and unsaturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, this definition shall include but is not limited to methyl (Me), ethyl (Et), propyl (Pr), butyl (Bu), pentyl, hexyl, heptyl, ethenyl, propenyl, butenyl, penentyl, hexenyl, isopropyl (i-Pr), isobutyl (i-Bu), tert- butyl (f-Bu), sec-butyl (s-Bu), isopentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopen- tyl, cyclohexyl, cyclopentenyl, cyclohexenyl, methylcyclopropyl, ethylcyclohexenyl, butenylcyclopentyl, and the like.
The term "substituted alkyl" represents an alkyl group as defined above wherein the substitutents are independently selected from halo, cyano, nitro, trihalomethyl, car- bamoyl, hydroxy, oxo, COR5, C Cgalkyl, CrC6alkyloxy, aryloxy, arylCrC6alkyloxy, thio, CrC6alkylthio, arylthio, arylCrC6alkylthio, NR7R8, CrCgalkylamino, arylamino, arylCrC6alkylamino, di(arylC C6alkyl)amino, C1-C6alkylcarbonyl, arylC,- C6alkylcarbonyl, C C6alkylcarboxy, arylcarboxy, arylCrC6alkylcarboxy, C C6alkylcarbonyl-amino, -C1-C6alkylaminoCOR11, arylCrC6alkylcarbonylamino, tetra- hydrofuranyl, morpholinyl, piperazinyl, -CONR7R8, -C C6alkyl-CONR7R8, or a saturated or partial saturated cyclic 5, 6 or 7 membered amine, imide or lactam; wherein R„ is hydroxy, C C6alkyl, aryl, arylCrC6alkyl, C1-C6alkyloxy, aryloxy, arylCr 25
C6alkyloxy and R5 is defined as above or NR7R8, wherein R7, R8 are defined as above.
The term "saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring sy- stem" represents but are not limit to aziridinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imida- zolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, 1 ,2,3-triazolyl, 1 ,2,4- triazolyl, morpholinyl, piperidinyl, thiomorpholinyl, piperazinyl, indolyl, isoindolyl, 1 ,2,3,4-tetrahydro-quinolinyl, 1 ,2,3,4-tetrahydro-isoquinolinyl, 1 ,2,3,4-tetrahydro- quinoxalinyl, indolinyl, indazolyl, benzimidazolyl, benzotriazolyl, purinyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, iminodibenzyl, iminostilbenyl.
The term "alkyloxy" (e.g. methoxy, ethoxy, propyloxy, allyloxy, cyclohexyloxy) represents an "alkyl" group as defined above having the indicated number of carbon atoms attached through an oxygen bridge. The term "alkyloxyalkyl" represents an "alkyloxy" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
The term "alkyloxyalkyloxy" represents an "alkyloxyalkyl" group attached through an oxygen atom as defined above having the indicated number of carbon atoms.
The term "aryloxy" (e.g. phenoxy, naphthyloxy and the like) represents an aryl group as defined below attached through an oxygen bridge.
The term "arylalkyloxy" (e.g. phenethyloxy, naphthylmethyloxy and the like) represents an "arylalkyl" group as defined below attached through an oxygen bridge. The term "arylalkyloxyalkyl" represents an "arylalkyloxy" group as defined above at- tached through an "alkyl" group defined above having the indicated number of carbon atoms.
The term "arylthio" (e.g. phenylthio, naphthylthio and the like) represents an "aryl" group as defined below attached through an sulfur bridge. The term "alkyloxycarbonyl" (e.g. methylformiat, ethylformiat and the like) represents an "alkyloxy" group as defined above attached through a carbonyl group. 26
The term "aryloxycarbonyi" (e.g. phenylformiat, 2-thiazolylformiat and the like) represents an "aryloxy" group as defined above attached through a carbonyl group. The term "arylalkyloxycarbonyl" (e.g. benzylformiat, phenyletylformiat and the like) represents an "arylalkyloxy" group as defined above attached through a carbonyl group.
The term "alkyloxycarbonylalkyl" represents an "alkyloxycarbonyl" group as defined above attached through an "alkyl" group as defined above having the indicated number of carbon atoms. The term "arylalkyloxycarbonylalkyl" represents an "arylalkyloxycarbonyl" group as defined above attached through an "alkyl" group as defined above having the indicated number of carbon atoms.
The term "alkylthio" (e.g. methylthio, ethylthio, propylthio, cyclohexenylthio and the like) represents an "alkyl" group as defined above having the indicated number of carbon atoms attached through a sulfur bridge.
The term "arylalkylthio" (e.g. phenylmethylthio, phenylethylthio, and the like) represents an "arylalkyl" group as defined above having the indicated number of carbon atoms attached through a sulphur bridge. The term "alkylthioalkyl" represents an "alkylthio" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
The term "arylalkylthioalkyl" represents an "arylalkylthio" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
The term "alkylamino" (e.g. methylamino, diethylamino, butylamino, N-propyl-N- hexylamino, (2-cyclopentyl)propylamino, hexenylamino, pyrrolidinyl, piperidinyl and the like) represents one or two "alkyl" groups as defined above having the indicated number of carbon atoms attached through an amine bridge. The two alkyl groups may be taken together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C 27
C6alkyl, aryl, arylC1-C6alkyl, hydroxy, oxo, C C6alkyloxy, C1-C6alkyloxyC1-C6alkyl, NR9R10, C1-C6alkylaminoC1-C6alkyl substituent wherein the alkyl and aryl groups are optionally substituted as defined in the definition section and R9 and R10 are defined as above.
The term "arylalkylamino" (e.g. benzylamino, diphenylethylamino and the like) represents one or two "arylalkyl" groups as defined above having the indicated number of carbon atoms attached through an amine bridge. The two "arylalkyl" groups may be taken together with the nitrogen to which they are attached forming a saturated, par- tially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing 3 to 14 carbon atoms and 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C1-C6alkyl, aryl, arylCrC6alkyl, hydroxy, oxo, C^-Cgalkyloxy, C1-C6alkyloxyC1-C6alkyl, NR9R10, C . CgalkylaminoC1-C6alkyl substituent wherein the alkyl and aryl groups are optionally substituted as defined in the definition section and R9 and R10 are defined as above.
The term "alkylaminoalkyl" represents an "alkyiamino" group attached through an alkyl group as defined above having the indicated number of carbon atoms. The term "arylalkylaminoalkyl" represents an "arylalkylamino" group attached through an alkyl group as defined above having the indicated number of carbon atoms. The term "arylalkyl" (e.g. benzyl, phenylethyl) represents an "aryl" group as defined below attached through an alkyl having the indicated number of carbon atoms or substituted alkyl group as defined above. The term "alkylcarbonyl" (e.g. cyclooctylcarbonyl, pentylcarbonyl, 3-hexenylcarbonyl) represents an "alkyl" group as defined above having the indicated number of carbon atoms attached through a carbonyl group.
The term "arylcarbonyl" (benzoyl) represents an "aryl" group as defined above attached through a carbonyl group. 28
The term "arylalkylcarbonyl" (e.g. phenylcyclopropylcarbonyl, phenylethylcarbonyl and the like) represents an "arylalkyl" group as defined above having the indicated number of carbon atoms attached through a carbonyl group. The term "alkylcarbonylalkyl" represents an "alkylearbonyl" group attached through an "alkyl" group as defined above having the indicated number of carbon atoms. The term "arylalkylcarbonylalkyl" represents an "arylalkylcarbonyl" group attached through an alkyl group as defined above having the indicated number of carbon atoms.
The term "alkylcarboxy" (e.g. heptylcarboxy, cyclopropylcarboxy, 3-pentenylcarboxy) represents an "alkylearbonyl" group as defined above wherein the carbonyl is in turn attached through an oxygen bridge.
The term "arylcarboxyalkyl" (e.g. phenylcarboxymethyl) represents an "arylcarbonyl" group defined above wherein the carbonyl is in turn attached through an oxygen bridge to an alkyl chain having the indicated number of carbon atoms. The term "arylalkylcarboxy" (e.g. benzylcarboxy, phenylcyclopropylcarboxy and the like) represents an "arylalkylcarbonyl" group as defined above wherein the carbonyl is in turn attached through an oxygen bridge. The term "alkylcarboxyalkyl" represents an "alkylcarboxy" group attached through an "alkyl" group as defined above having the indicated number of carbon atoms. The term "arylalkylcarboxyalkyl" represents an "arylalkylcarboxy" group attached through an "alkyl" group as defined above having the indicated number of carbon atoms. The term "alkylcarbonylamino" (e.g. hexylcarbonylamino, cyclopentylcarbonyl- aminomethyl, methylcarbonylammophenyl) represents an "alkylearbonyl" group as defined above wherein the carbonyl is in turn attached through the nitrogen atom of an amino group. The nitrogen atom may itself be substituted with an alkyl or aryl group. The term "arylalkylcarbonylamino" (e.g. benzylcarbonylamino and the like) repre- sents an "arylalkylcarbonyl" group as defined above wherein the carbonyl is in turn 29 attached through the nitrogen atom of an amino group. The nitrogen atom may itself be substituted with an alkyl or aryl group.
The term "alkylearbonylaminoalkyl" represents an "alkylcarbonylamino" group attached through an "alkyl" group as defined above having the indicated number of carbon atoms. The nitrogen atom may itself be substituted with an alkyl or aryl group. The term "arylalkylcarbonylaminoalky." represents an "arylalkylcarbonylamino" group attached through an "alkyl" group as defined above having the indicated number of carbon atoms. The nitrogen atom may itself be substituted with an alkyl or aryl group.
The term "alkylcarbonylaminoalkylcarbonyl" represents an alkylearbonylaminoalkyl group attached through a carbonyl group. The nitrogen atom may be further substituted with an "alkyl" or "aryl" group.
The term "aryl" represents an unsubstituted, mono-, di- or trisubstituted monocyclic, polycyclic, biaryl and heterocyclic aromatic groups covalently attached at any ring position capable of forming a stable covalent bond, certain preferred points of attachment being apparent to those skilled in the art (e.g., 3-indolyl, 4-imidazolyl). The aryl substituents are independently selected from the group consisting of halo, nitro, cyano, trihalomethyl, C1-C6alkyl, aryl, arylC C6alkyl, hydroxy, COR5, C C6alkyloxy, C1-C6alkyloxyC1-C6alkyl, aryloxy, arylC^-Cgalkyloxy, arylC1-C6alkyloxyC1-C6alkyl, thio, CrC6alkylthio, C1-C6alkylthioC1-C6alkyl, arylthio, arylCrCgalkylthio, arylCr CgalkylthioC Cgalkyl, NR8R9, C1-C6-alkylamino, C1-C6alkylaminoC1-C6alkyl, arylamino, arylC1-C6alkylamino, arylC1-CgalkylaminoC1-C6alkyl, di(arylCrC6alkyl)aminoCr C6alkyl, C C6alkylcarbonyl, C1-C6alkylcarbonylC1-C6alkyl, arylC Cgalkylcarbonyl, arylC1-C6alkylcarbonylC1-Cgalkyl, CrC6alkylcarboxy, C1-C6alkylcarboxy-C1-C6alkyl, arylCrC6alkylcarboxy, arylC1-C6alkyl-carboxyC1-Cgalkyl, carboxyC1-C6alkyloxy, C C6alkylcarbonylamino, C1-C6alkylcarbonyl-aminoC1-C6alkyl, -carbonylNR7C CgalkylCORn, arylC C6alkylcarbonyl-amino, arylC1-C6alkylcarbonylaminoC1-C6alkyl, - CONR8R9, or -C,-C6alkyl-CONR8R9; wherein R7, R8, R9, and R„ are defined as above and the alkyl and aryl groups are optionally substituted as defined in the definition section; 30
The definition of aryl includes but is not limited to phenyl, biphenyl, indenyl, fluorenyl, naphthyl (1-naphthyl, 2-naphthyl), pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imida- zolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazoM-yl, 1,2,3-triazol-2-yl 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiophenyl (2-thiophenyl, 3-thiophenyl, 4-thiophenyl, 5- thiophenyl), furanyl (2-furanyl, 3-furanyl, 4-furanyl, 5-furanyl), pyridyl (2-pyridyl, 3- pyridyl, 4-pyridyl, 5-pyridyl), 5-tetrazolyl, pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5- pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7- quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5- isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2- benzo[bjfuranyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6- benzo[b]furanyl, 7-benzo[bjfuranyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro- benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5- (2,3-dihydro-benzo-[bjfuranyl), 6-(2,3-dihydro-benzo-[bjfuranyl), 7-(2,3-dihydro- benzo[b]furanyl)), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7- benzo[b]thiophenyl), 2,3-dihydro-benzo[b]-thiophenyl (2-(2,3-dihydro- benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]-thiophenyl), 4-(2,3-dihydro- benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]-thiophenyl), 6-(2,3-dihydro- benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]-thiophenyl)), 4,5,6,7-tetrahydro- benzo[bjthiophenyl (2-(4,5,6,7-tetrahydro-benzo-[b]thiophenyl), 3-(4,5,6,7-tetrahydro- benzo-[bjthiophenyl), 4-(4,5,6,7-tetrahydro-benzo[b]thiophenyl), 5-(4, 5,6,7- tetrahydro-benzo-[b]thiophenyl), 6-(4,5,6,7-tetrahydro-benzo-[b]thiophenyl), 7- (4,5,6,7-tetrahydro-benzo[b]thiophenyl)), 4,5,6, 7-tetrahydro-thieno[2,3-c]pyridyl (4- (4,5,6,7-tetrahydro-thieno[2,3-cjpyridyl), 5-4,5,6,7-tetrahydro-thieno[2,3-c]pyridyl), 6- (4,5,6,7-tetrahydro-thieno[2,3-c]pyridyl), 7-(4,5,6,7-tetrahydro-thieno[2,3-cjpyridyl)), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), isoin- dolyl (1-isoindolyl, 2-isoindolyl, 3-isoindolyl, 4-isoindolyl, 5-isoindolyl, 6-isoindolyl, 7- isoindolyl), 1 ,3-dihydro-isoindolyl (1-(1,3-dihydro-isoindolyl), 2-(1 ,3-dihydro- 31 isoindolyl), 3-(1 ,3-dihydro-isoindolyl), 4-(1 ,3-dihydro-isoindolyI), 5-(1 ,3-dihydro- isoindolyl), 6-(1 ,3-dihydro-isoindolyl), 7-(1 ,3-dihydro-isoindolyl)), indazole (1- indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1 -benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6- benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benz-oxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzo-thiazolyl, 4- benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1- carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,fjazepine (5H- dibenz[b,f]azepin-1-yi, 5H-dibenz-[b,fjazepine-2-yl, 5H-dibenz[b,fjazepine-3-yl, 5H- dibenz-[b,fjazepine-4-yI, 5H-dibenz[b,fj-azepine-5-yl), 10,11-dihydro-5H- dibenz[b,f]azepine (10,11 -dihydro-5H-dibenz[b,fjazepine-1 -yl, 10, 11 -dihydro-5H- dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,fjazepine-3-yl, 10,11-dihydro-5H- dibenz-[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,fjazepine-5-yl), piperidinyl (2- piperidinyl, 3-piperidinyl, 4-piperidinyl), pyrrolidinyl (1 -pyrrolidinyl, 2-pyrrolidinyl, 3- pyrrolidinyl), phenylpyridyl (2-phenyl-pyridyl, 3-phenyl-pyridyl, 4-phenylpyridyl), phen- ylpyrimidinyl (2-phenylpyrimidinyl, 4-phenyl-pyrimidinyl, 5-phenylpyrimidinyl, 6- phenylpyrimidinyl), phenylpyrazinyl, phenylpyridazinyl (3-phenylpyridazinyl, 4- phenylpyridazinyl, 5-phenyl-pyridazinyl).
The term "arylcarbonyl" (e.g. 2-thiophenylcarbonyl, 3-methoxy-anthrylcarbonyl, oxa- zolylcarbonyl) represents an "aryl" group as defined above attached through a carbonyl group.
The term "arylalkylcarbonyl" (e.g. (2,3-dimethoxyphenyl)-propylcarbonyl, (2- chloronaphthyl)pentenylcarbonyl, imidazolylcyclo-pentylcarbonyl) represents an "arylalkyl" group as defined above wherein the "alkyl" group is in turn attached through a carbonyl.
The compounds of the present invention have asymmetric centers and may occur as racemates, racemic mixtures, and as individual enantiomers or diastereoisomers, with all isomeric forms being included in the present invention as well as mixtures thereof. 32
Pharmaceutically acceptable salts of the compounds of formula 1 , where a basic or acidic group is present in the structure, are also included within the scope of this invention. When an acidic substituent is present, such as -COOH, 5-tetrazolyl or - P(O)(OH)2ι there can be formed the ammonium, morpholinium, sodium, potassium, barium, calcium salt, and the like, for use as the dosage form. When a basic group is present, such as amino or a basic heteroaryl radical, such as pyridyl, an acidic salt, such as hydrochloride, hydrobromide, phosphate, sulfate, trifluoroacetate, trichloroa- cetate, acetate, oxalate, maleate, pyruvate, malonate, succinate, citrate, tartarate, fumarate, mandelate, benzoate, cinnamate, methanesulfonate, ethane sulfonate, pi- crate and the like, and include acids related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, S6, 2 (1977) and incorporated herein by reference, can be used as the dosage form.
Also, in the case of the -COOH or -P(O)(OH)2 being present, pharmaceutically acceptable esters can be employed, e.g., methyl, tert-butyl, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of the invention. The term "therapeutically effective amount" shall mean that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other.
PREFERRED EMBODIMENTS OF THE INVENTION
Compounds of Formula 1a are preferred compounds of the invention
Formula 1a 33
wherein
A is together with the double bond in Formula 1a furo[2,3-b]pyridyl, thieno[2,3- bjpyridyl, pyrrolo[2,3-bjpyridyl, furo[2,3-c]pyridyl, thieno[2,3-c]pyridyl, pyrrolo[2,3- cjpyridyl, furo[3,2-c]pyridyl, thieno[3,2-c]pyridyl, pyrrolo[3,2-c]pyridyl, furo[3,2- djpyridyl, thieno[3,2-djpyridyl, pyrrolo[3,2-d]pyridyl, furo[2,3-djpyrimidyl, thieno[2,3- djpyrimidyl, pyrrolo[2,3-d]pyrimidyl, furo[2,3-bjpyrazinyl, thieno[2,3-b]pyrazinyl, pyr- rolo[2,3-b]pyrazinyl, furo[2,3-c]pyridazinyl, thieno[2,3-c]pyridazinyl, pyrrolo[2,3- cjpyridazinyl, furo[2,3-d]pyridazinyl, thieno[2,3-d]pyridazinyl, pyrrolo[2,3-d]pyridazinyl, furo[3,2-cjpyridazinyl, thieno[3,2-c]pyridazinyl or pyrrolo[3,2-c]pyridazinyl;
R, is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 or selected from the following 5- membered heterocycles:
H ,N. o'VOH s'Nv0H H ^ °H °-s°
X X T o
[J o
N S~0 0M s'Ny-°H
X = prm )VSH
N VOH HN' °H
X X Nr0H pr l °
/ H
0 HΪ >
or R- is
'14 34
wherein R12, R13, and R14 are independently hydrogen, C1-Cβal yll aryl, arylC C6alkyl and the alkyl and aryl groups are optionally substituted;
R2 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 , or selected from the following 5- membered heterocycles:
H
,N. N N ft " o'VOH s'Nv0H HN- °H °-s°
X X T o N
N S=0 o' OH S' OH 6 =N
/^=N pr™ N VSH
X
H
N'V0H HN' -0H
^=N fr0" pr™ / H
/ O/
HN ■S
R3, R16 and R17are independently hydrogen, halo, nitro, cyano, trihalomethyl, C,- Cβalkyl, aryl, arylC^Cg-alkyl, hydroxy, carboxy, carboxyC Cgalkyl, C^Cgalkyloxy- carbonyl, aryloxycarbonyi, arylCrC6alkyloxycarbonyl, C1-C6alkyloxy, CrC6alkyl- oxyC C6alkyl, aryloxy, arylC^Cgalkyloxy, arylC1-C6alkyl-oxyC1-C6alkyl, thio, Cr
C6alkylthio, C1-C6alkylthioC1-C6alkyl, arylthio, arylCrC6alkylthio, arylC CgalkylthioC^ C6alkyl, NR7R8, CTCgalkyl-aminoC Cgalkyl, arylC1-CgalkylaminoC1-C6alkyl, di(arylC1- C6alkyl)-aminoCrC6alkyl, C C6alkylcarbonyl, C1-C6alkylcarbonylC1-C6alkyl, arylC^ C6alkylcarbonyl, arylC1-C6alkylcarbonylC1-C6alkyl, CrC6alkyl-carboxy, CrC6alkyl- carboxyCrC6-alkyl, arylcarboxy, arylC1-C6alkyl-carboxy, arylC1-C6alkylcarboxyC1- C6alkyl, C1-C6alkylcarbonylamino, C1-C6alkylcarbonyl-aminoC1-C6alkyl, -carbonylNR7C1-C6alkylCOR11 ) arylCrC6alkyl-carbonylamino, arylC 35
CgalkylcarbonylaminoCrCgalkyl, CONR7R8, or CrC6alkylCONR7R8 wherein the alkyl and aryl groups are optionally substituted and R„ is NR7R8, or C1-C6alkylNR7R8; or R3 is
wherein R12, R13, and R14 are independently hydrogen, C C6alkyl, aryl, arylC1-C6alkyl and the alkyl and aryl groups are optionally substituted;
R4 is hydrogen, hydroxy, CrC6alkyl, aryl, arylCrC6alkyl, NR7R8, C^Cgalkyloxy; wherein the alkyl and aryl groups are optionally substituted;
R5 is hydroxy, CrC6alkyl, aryl, arylC1-C6alkyl, CF3, NR7R8; wherein the alkyl and aryl groups are optionally substituted;
R6 is hydrogen, CrC6alkyl, aryl, arylC Cgalkyl; wherein the alkyl and aryl groups are optionally substituted;
R7 and R8 are independently selected from hydrogen, C C6alkyl, aryl, arylC C6alkyl, C1-C6alkyl-carbonyl, arylcarbonyl, arylCrC6alkyl-carbonyl, CrC6alkyl-carboxy or a- rylC1-C6alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C C6alkyl, aryl, arylC1-C6alkyl, hydroxy, C^Cgalkyloxy, arylC1-C6alkyloxy, C1-C6alkyloxyC1-C6alkyl, NR9R10 or C^Cgalkylamino-C Cgalkyl, wherein R9 and R10 are independently selected from hydrogen, C C6alkyl, aryl, a- rylC^Cgalkyl, CrC6alkylcarbonyl, arylcarbonyl, arylCrC6alkylcarbonyl, CrC6alkyl- 36 carboxy or arylC^Cgalkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or
R7 and R8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine or lactam;
Also, compounds of Formula 1c are preferred compounds of the invention
■£$ Formula 1c
wherein A is together with the double bond in Formula 1c quinolizinyl, quinolinyl, iso- quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1 ,8-naphthyridinyl, chromanyl, thiochromanyl, isochromanyl or isothiochromanyl;
R1 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 or selected from the following 5- membered heterocycles:
37
.N. OH 0, '° N N o"VOH . OH HN Hϊ'8o
H o
N'N S=0 θ'VOH S'V0H N'V0H N'VSH -ό )=N )=N -0 -0
pr " fr0H pr fy° o
y^ti or R, is
U I" H
14
R12 O
wherein R12, R13, and R14 are independently hydrogen, C Cgalkyl, aryl, arylCrC6alkyl and the alkyl and aryl groups are optionally substituted;
R2 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2,
CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 , or selected from the following 5- membered heterocycles:
38
H
,N. H N N ° s9 ft " o N OH s'V0H HN^ Hϊ 0
X X =N
N S'O o Ny-OH s'V y V=N μ0H pr _VSH
pr™ H μN'V°H frM frm / H
ι Oι
HN S
R3, R16 and R17are independently hydrogen, halo, nitro, cyano, trihalomethyl, C C6alkyl, aryl, arylC1-Cg-alkyl, hydroxy, carboxy, carboxyCrC6alkyl, C^Cgalkyloxy- carbonyl, aryloxycarbonyi, arylC^Cgalkyloxycarbonyl, CrC6alkyloxy, C C6alkyl- oxyCrC6alkyl, aryloxy, arylC1-C6alkyloxy, arylCϊ-Cgalkyl-oxyCrCgalkyl, thio, Cr C6alkylthio, C CgalkylthioC Cgalkyl, arylthio, arylC1-C6alkylthio, arylCrC6alkylthioCr C6alkyl, NR7R8, C1-Cgalkyl-aminoC1-C6alkyl, arylC1-C6alkylaminoC1-C6alkyl, di(arylC1- C6alkyl)-aminoC Cealkyl, C^Cgalkylcarbonyl, C1-C6alkylcarbonylC1-C6alkyl, aιylCr Cgalkylcarbonyl, arylC1-C6alkylcarbonylC1-C6alkyl, C C6alkyl-carboxy, CrC6alkyl- carboxyC1-C6-alkyl, arylcarboxy, arylCrC6alkyl-carboxy, arylCrCgalkylcarboxyC,- C6alkyl, C C6alkylcarbonylamino, C1-C6alkylcarbonyl-aminoC1-C6alkyl, -carbonylNR7C1-C6alkylCOR11, arylC1-C6alkyl-carbonylamino, arylCr C6alkyicarbonylaminoC1-C6alkyl, CONR7R8, or CrC6alkylCONR7R8 wherein the alkyl and aryl groups are optionally substituted and R is NR7R8, or C C6alkylNR7R8; or R3 is
u ?13 H R« ° 39 wherein R12, R13, and R14 are independently hydrogen, CrC6alkyl, aryl, arylCrC6alkyl and the alkyl and aryl groups are optionally substituted;
R4 is hydrogen, hydroxy, CrC6alkyl, aryl, arylCrC6alkyl, NR7R8, CrC6alkyloxy; whe- rein the alkyl and aryl groups are optionally substituted;
R5 is hydroxy, C Cgalkyl, aryl, arylC^Cgalkyl, CF3, NR7R8; wherein the alkyl and aryl groups are optionally substituted;
R6 is hydrogen, CrC6alkyl, aryl, arylCrC6alkyl; wherein the alkyl and aryl groups are optionally substituted;
R7 and R8 are independently selected from hydrogen, CrC6alkyl, aryl, arylC C6alkyl, C^Cgalkyl-carbonyl, arylcarbonyl, arylC1-C6alkyl-carbonyl, C1-C6alkyl-carboxy or a- rylC1-C6alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one CrCgalkyl, aryl, arylC Cgalkyl, hydroxy, C C6alkyloxy, arylCrC6alkyloxy, CrCgalkyloxyCTCgalkyl, NR9R10 or C1-C6alkylamino-C1-C6alkyl, wherein R9 and R10 are independently selected from hydrogen, CrCgalkyl, aryl, a- rylCrC6alkyl, CrC6alkylcarbonyl, arylcarbonyl, arylCrC6alkylcarbonyl, CrC6alkyl- carboxy or arylCrC6alkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine or lactam;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical iso- mer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms. 40
Also, compounds of Formula 1d are preferred compounds of the invention
*17
R, ^ 16 N
R,' X:
Formula 1d
whereinA is together with the double bond in Formula 1d 4,5-dihydro-thieno[2,3- bjfuranyl, 4,5-dihydro-thieno[2,3-b]thiophenyl, 4,5-dihydro-thieno[2,3-b]pyrrolyl, thieno[3,2-d]isothiazolyl, thieno[3,2-d]thiazolyl, thieno[2,3-d]thiazolyl, thieno[2,3- c]pyrrolyl-4,6-dione, 1 H-thieno[2,3-d]imidazoiyl, 6H-thieno[2,3-b]pyrrolyl, 5,6-dihydro- 4H-thieno[2,3-c]pyrrolyl or 4H-thieno[3,2-bjpyrrolyl;
R is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 or selected from the following 5- membered heterocycles:
H
,N. N N
W Jl o'VOH S'N OH HN OH HN ;s
I
-N -N
Li —
N N S-0 o'VOH S'VOH N'V0H N'N SH ό M )-ό "0
N'V-T0H HN' 0H Vϊ0H ^ r°H <Cr°
o
HN' y^ti 41 or R. is o R.
Λ ι « H
"14
R12 O
wherein R12, R13, and R14 are independently hydrogen, C C6alkyl, aryl, arylCrC6alkyl and the alkyl and aryl groups are optionally substituted;
R2 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 , or selected from the following 5- membered heterocycles:
H ,N. o'VOH s'Nv0H HN^ OH °-s° o
X X
« [Nj,on Λ N S=0 o
X μ'VOH μ s'V0H prw pr
N'V°H HN' ^0H
\=N frm pr°" -N / H p
R3 R16 and R17 are independently hydrogen, halo, nitro, cyano, trihalomethyl, Cr C6alkyl, aryl, arylC1-C6-alkyl, hydroxy, carboxy, carboxyCrC6alkyl, C,-Cgalkyloxy- carbonyl, aryloxycarbonyi, arylC^Cgalkyloxycarbonyl, C C6alkyloxy, C^Cgalkyl- oxyC1-C6alkyl, aryloxy, arylC C6alkyloxy, arylC^Cgalkyl-oxyC Cgalkyl, thio, C,- C6alkylthio, C CgalkylthioC.-Cgalkyl, arylthio, arylCrC6alkylthio, arylC1-C6alkylthioC1- CgalkyI, NR7R8, C1-C6alkyl-aminoC1-Cgalkyl, arylC1-C6alkylaminoC1-Cgalkyl, di(arylCr Cgalky -aminoCrCgalkyl, CrCgalkyl-carbonyl, C1-C6alkylcarbonylC1-C6alkyl, arylC C6alkylcarbonyl, arylC1-C6alkylcarbonylC1-Cgalkyl, C C6alkyl-carboxy, C 42
C6alkylcarboxyC1-C6-alkyl, arylcarboxy, arylCrCgalkyl-carboxy, arylCr CgalkylcarboxyC^Cgalkyl, CrC6alkylcarbonylamino, C1-C6alkylcarbonyl-aminoC1- C6alkyl, -carbonylNR7C1-C6alkylCOR11, arylC^Cgalkyl-carbonylamino, arylC CgalkylcarbonylaminoC.-Cgalkyl, CONR7R8, or CrC6alkylCONR7R8 wherein the alkyl and aryl groups are optionally substituted and R is NR7R8, or C1-C6alkylNR7R8; or
R3 is ϊ? fi H
R12 O
wherein R12, R13, and R14 are independently hydrogen, CrC6alkyl, aryl, aιylC C6alkyl and the alkyl and aryl groups are optionally substituted;
R4 is hydrogen, hydroxy, CrC6alkyl, aryl, arylCrC6alkyl, NR7R8, CrC6alkyloxy; whe- rein the alkyl and aryl groups are optionally substituted;
R5 is hydroxy, CrC6alkyl, aryl, arylC C6alkyl, CF3, NR7R8; wherein the alkyl and aryl groups are optionally substituted;
R6 is hydrogen, C Cgalkyl, aryl, arylC1-C6alkyl; wherein the alkyl and aryl groups are optionally substituted;
R7 and R8 are independently selected from hydrogen, CrCgalkyl, aryl, arylCrC6alkyl, C1-C6alkyl-carbonyl, arylcarbonyl, arylC1-C6alkylcarbonyl, C Cβalkyl-carboxy or a- rylC1-C6alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or
R7 and R8 are taken together with the nitrogen to which they are attached forming a cyclic or bicyclic system containing 3 to 11 carbon atoms and 0 to 2 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one CrC6alkyl, aryl, arylC1-C6alkyl, hydroxy, C C6alkyloxy, arylC,-C6alkyloxy, C1-C6alkyloxyC1-C6alkyl, NR9R10 or C1-C6alkylamino-C1-C6alkyl, wherein R9 and R10 are independently selected from hydrogen, C C6alkyl, aryl, a- 43 rylCrC6alkyl, CrC6alkylcarbonyl, arylcarbonyl, arylC C6alkylcarbonyl, CrCgalkyl- carboxy or arylC C6alkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or
R7 and R8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine or lactam;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical iso- mer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
Further, preferred compounds of the invention are compounds of formula la, Ic or Id wherein R16 and R17 are hydrogen.
The invention will in its broadest aspect cover the following compounds: of Formula 1b:
Rl7V ,R1
R ^ ^
Formula 1b
wherein A is together with the double bond in Formula 1b; aryl;
R is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8; or selected from the following 5-membered heterocycles: 44
H 0 '°
N \\'N " θ'VOH S'V0H HN'V0H HN'S
N'N S=0 θ'VOH S'V0H N'V0H N' SH y-ό )=N >=N -O }-O
N' °H HN - OH OH OH
/ H p
HN'έb
or R- is o R.
RV12 O ^
wherein R12, R13, and R14 are independently hydrogen, C1-Cβalkyl, aryl, arylC1-C6alkyl and the alkyl and aryl groups are optionally substituted;
R2 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8; or selected from the following 5-membered heterocycles:
45
H ,N. o'VOH s'Nv-0H HN^ OH ° s9 HN L 0
X X
[J o
N S-0 o'V y μOH μ s'V0H prw p-*"
>Y0H HN' °H pr prm -N / H p
HN-
R3, R16 and R17are independently hydrogen, halo, nitro, cyano, trihalomethyl, C C6alkyl, aryl, arylCrC6alkyl, hydroxy, oxo, carboxy, carboxyC1-C6alkyl, C,- Cgalkyloxycarbonyl, aryloxycarbonyi, aryl^-Cgalkyloxycarbonyl, C^Cgalkyloxy, C CgalkyloxyC^Cgalkyl, aryloxy, arylC1-C6alkyloxy, arylC1-C6alkyloxyC1-C6alkyl, thio, C,- C6alkylthio, C C6alkylthioCrC6alkyl, arylthio, arylCrC6alkylthio, arylC CgalkylthioC C6alkyl, NR7R8, C CgalkylaminoC Cgalkyl, arylC1-C6alkylaminoC1-C6alkyl, di(arylCr C6alkyl)aminoC1-C6alkyl, C1-C6alkylcarbonyl, C1-C6alkylcarbonyl-C1-C6alkyl, arylCr Cgalkylcarbonyl, arylC1-C6alkyicarbonylC1-C6alkyl, CTCgalkylcarboxy, C
C6alkylcarboxyC1-C6-alkyl, arylcarboxy, arylcarboxyC C6alkyl, arylC C6alkylcarboxy, arylC1-C6alkylcarboxyC1-C6alkyl, CrC6alkylcarbonylamino, Cr C6alkylcarbonylaminoC1-C6alkyl, -carbonylNR7C1-C6alkylCOR11, arylC1-C6alkyl- carbonylamino, arylC C6alkylcarbonylaminoC1-C6alkyl, CONR7R8, or Cr C6alkylCONR7R8 wherein the alkyl and aryl groups are optionally substituted and Rnι is NR7R8, or CrC6alkylNR7R8; or R3 is
>« H
R 14
R12 O
wherein R12, R13, and R14 are independently hydrogen, CrC6alkyl, aryl, arylC1-C6alkyl and the alkyl and aryl groups are optionally substituted; 46
R4 is hydrogen, hydroxy, CrC6alkyl, aryl, arylCrC6alkyl, NR7R8, C1-C6alkyloxy; wherein the alkyl and aryl groups are optionally substituted;
R5 is hydroxy, C Cβalkyl, aryl, arylCrC6alkyl, CrC6alkyloxy, CrC6alkyl-oxyCr
C6alkyloxy, aryloxy, arylC C6alkyloxy, CF3, NR7R8; wherein the alkyl and aryl groups are optionally substituted;
R6 is hydrogen, C,-Cβalkyl, aryl, arylC1-C6alkyl; wherein the alkyl and aryl groups are optionally substituted;
R7 and R8 are independently selected from hydrogen, C1-C6alkyl, aryl, arylC1-C6alkyl, CrC6alkylcarbonyl, arylcarbonyl, arylCrC6alkylcarbonyl, CrC6alkylcarboxy or arylC,- C6alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing from 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from nitrogen, oxygen or sulfur, the ring system can optionally be substituted with at least one CrCβalkyl, aryl, arylC C6alkyl, hydroxy, oxo, C1-C6alkyloxy, arylC1-C6alkyloxy, C1-C6alkyloxyC1-Cgalkyl, NR9R10 or C1-C6alkylaminoC1-C6alkyl, wherein R9 and R10 are independently selected from hydrogen, C Cgalkyl, aryl, arylC1-C6alkyl, Cr C6alkylcarbonyl, arylcarbonyl, arylC1-Cgalkyicarbonyl, C1-C6alkylcarboxy or arylC C6alkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine, imide or lactam;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical iso- mer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms. 47
Particular preferred compounds of the invention are those compounds of formula I wherein R is 5-tetrazolyl, i.e.
H -N. λN or COOH and R2 is COR5. In particular, preferred compounds are those wherein R5 is OH and R4 is hydrogen.
The following compounds are preferred:
2-(Oxalyl-amino)-thieno[2,3-bjpyridine-3-carboxylic acid; 6-(Oxalyl-amino)-thieno[2,3-d]pyrimidine-5-carboxylic acid;
6-(Oxalyl-amino)-thieno[2,3-b]pyrazine-7-carboxylic acid;
3-(Oxalyl-amino)-thieno[2,3-bjpyridine-2-carboxylic acid;
5-(Oxalyl-amino)-thieno[2,3-djpyrimidine-6-carboxylic acid;
7-(Oxalyl-amino)-thieno[2,3-bjpyrazine-6-carboxylic acid; 5-(Oxalyl-amino)-2,3-dihydro-thieno[2,3-b]furan-4-carboxylic acid;
2-(Oxalyl-amino)-4,5-dihydro-thieno[2,3-bjthiophene-3-carboxylic acid;
5-(Oxalyl-amino)-thieno[3,2-d]isothiazole-4-carboxylic acid;
5-(Oxalyl-amino)-thieno[3,2-d]thiazole-6-carboxylic acid;
5-(Oxalyl-amino)-thieno[2,3-d]thiazole-6-carboxylic acid; 2-(Oxalyl-amino)-4,6-dioxo-5,6-dihydro-4H-thieno[2,3-c]pyrrole-3-carboxylic acid;
5-(Oxalyl-amino)-1 H-thieno[2,3-djimidazole-6-carboxylic acid;
2-(Oxalyl-amino)-6H-thieno[2,3-bjpyrrole-3-carboxylic acid;
2-(Oxalyl-amino)-5,6-dihydro-4H-thieno[2,3-c]pyrrole-3-carboxylic acid;
2-(Oxalyl-amino)-4H-thieno[3,2-b]pyrrole-3-carboxylic acid; 2-(Oxalyl-amino)-quinoline-3-carboxylic acid;
3-(Oxalyl-amino)-quinoline-2-carboxylic acid;
4-(Oxalyl-amino)-quinoline-3-carboxylic acid;
3-(Oxalyl-amino)-quinoline-4-carboxylic acid;
5-(Oxalyl-amino)-quinoline-6-carboxylic acid; 48 -(Oxalyl-amino)-isoquinoline-3-carboxylic acid; 3-(Oxalyl-amino)-isoquinoline-4-carboxylic acid; 7-(Oxalyl-amino)-quinoxaline-6-carboxylic acid; 2-(Oxalyl-amino)-[1 ,8]naphthyridine-3-carboxylic acid;
PHARMACOLOGICAL METHODS
The compounds are evaluated for biological activity with a truncated form of PTP1B (corresponding to the first 321 amino acids), which is expressed in E. coli and purified to apparent homogeneity using published procedures well-known to those skilled in the art. The enzyme reactions are carried out using standard conditions essentially as described by Burke et al. (Biochemistry 35; 15989-15996 (1996)). The assay conditions are as follows. Appropriate concentrations of the compounds of the invention are added to the reaction mixtures containing different concentrations of the substrate, p-nitrophenyl phosphate (range: 0.16 to 10 mM - final assay concentration). The buffer used is 100 mM sodium acetate pH 5.5, 50 mM sodium chloride, 0.1 % (w/v) bovine serum albumin and 5 mM dithiothreitol (total volume 100 ml). The reaction is started by addition of the enzyme and carried out in microtiter plates at 25° C for 60 minutes. The reactions are stopped by addition of NaOH. The enzyme activity is determined by measurement of the absorbance at 405 nm with appropriate cor- reetions for absorbance at 405 nm of the compounds and p-nitrophenyl phosphate. The data are analyzed using nonlinear regression fit to classical Michaelis Menten enzyme kinetic models. Inhibition is expressed as K, values in μM. The results of representative experiments are shown in Table 1
Table 1
Inhibition of classical PTP1B by compounds of the invention
PTP1B
Example no. K, values (μM) 1 330 49
Further, the compounds are evaluated for biological activity as regards their effect as inhibitors of PTPα in essentially the same way as described for inhibition of PTP1 B. Derived from their activity as evaluated above the compounds of the invention may be useful in the treatment of diseases selected from the group consisting of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance and obesity. Furthermore, derived from their activity as evaluated above, the compounds of the invention may be useful in the treatment of diseases selected from the group consisting of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferati- ve disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
THE SYNTHESIS OF THE COMPOUNDS
In accordance with one aspect of the invention, the compounds of the invention are prepared as illustrated in the following reaction scheme:
Method A
By allowing an amino substituted aryl or heteroaryl (I) to react with an acid chloride of formula (II), wherein R1 f R2, R3, R4, R16 and R17 are defined as above. 50
Method B
H .N.
R15COOH + R12NH2 + R„CHO + R14NC N T R
«1 (I) (II) (III) (IV)
By allowing a carboxylic acid (I), a primary amine (II) and an aldehyde (III) to react with a isocyanide (IV) wherein R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, CrC6alkyl, aryl, arylC Cgalkyl as defined above and the alkyl and aryl groups are optionally substituted as defined above; or R12, R13, R14, and R15 are independently selected from
Rl R4
wherein Y indicates attachment point for R12, R13, R14, and R15 and A, R, R2 and R4 are defined as above. In a preferred method, the above described four component Ugi reaction can be carried out by attaching any one of the components to a solid support. Hence, the synthesis can be accomplished in a combinatorial chemistry fashion.
General procedure for the Preparation of Acetoxymethyl Esters (C.Schultz et al, The Journal of Biological Chemistry, 1993, 268, 6316-6322.): A carboxylic acid (1 equivalent) was suspended in dry acetonitrile (2 ml per 0.1 mmol). Diisopropyl amine (3.0 equivalents) was added followed by bromomethyl acetate (1.5 equivalents). The mixture was stirred under nitrogen overnight at room temperature. Acetonitrile was removed under reduced pressure to yield an oil which was diluted in ethylacetate and washed water (3 x). The organic layer was dried over anhydrous magnesium sulfate. Filtration followed by solvent removal under reduced pressure afforded a crude oil. The product was purified by column chromatography on silica gel, using an appropriate solvent system. 51
The present invention also has the objective of providing suitable topical, oral, and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compounds of the present invention may be administered orally as tablets, aqueous or oily suspensions, lozenges, troches, powders, granules, emulsions, capsules, syrups or elixirs. The composition for oral use may contain one or more agents selected from the group of sweetening agents, flavoring agents, coloring agents and preserving agents in order to produce pharmaceutically elegant and palatable preparations. The tablets contain the acting ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents, such as corn starch or alginic acid; (3) binding agents, such as starch, gelatin or acacia; and (4) lubricating agents, such as magnesium stearate, stearic acid or talc. These tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. Coating may also be performed using techniques described in the U.S. Patent Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspension. Such expicients may be (1) suspending agent such as sodium carboxymethyl cellulose, methyl cellulose, hy- droxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth 52 and gum acacia; (2) dispersing or wetting agents which may be (a) naturally occurring phosphatide such as lecithin; (b) a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate; (c) a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethylen- oxycetanol; (d) a condensation product of ethylene oxide with a partial ester derived from a fatty acid and hexitol such as polyoxyethylene sorbitol monooleate, or (e) a condensation product of ethylene oxide with a partial ester derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol. Among the acceptable vehi- cles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The Compounds of the invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. The compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidyl-cholines. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula 1 are employed. 53
Dosage levels of the compounds of the present invention are of the order of about 0.5 mg to about 100 mg per kilogram body weight, with a preferred dosage range between about 20 mg to about 50 mg per kilogram body weight per day (from about 25 mg to about 5 g's per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain 5 mg to 1 g of an active compound with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 5 mg to about 500 mg of active ingredient.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. The dosage needs to be individualized by the clinician.
EXAMPLES
The process for preparing compounds of Formula 1 and preparations containing them is further illustrated in the following examples, which, however, are not to be construed as limiting.
Hereinafter, TLC is thin layer chromatography, CDCI3 is deuterio chloroform, CD3OD is tetradeuterio methanol and DMSO-d6 is hexadeuterio dimethylsulfoxide. The structures of the compounds are confirmed by either elemental analysis or NMR, where peaks assigned to characteristic protons in the title compounds are presented where appropriate. 1H NMR shifts (δH) are given in parts per million (ppm) downfield from tetramethylsilane as internal reference standard. M.p.: is melting point and is given in °C and is not corrected. Column chromatography is carried out using the 54 technique described by W.C. Still et al., J. Org. Chem. 43: 2923 (1978) on Merck silica gel 60 (Art. 9385). HPLC analyses are performed using 5μm C184 x 250 mm column eluted with various mixtures of water and acetonitrile, flow = 1 ml/min, as described in the experimental section.
Compounds used as starting material are either known compounds or compounds which can readily be prepared by methods known per se.
EXAMPLE 1
0" Na+ o
3-(Oxalyl-aminoVthienof2.3-b]pyridine-2-carboxylic acid, mono sodium salt:
To a stirred solution of 3-amino-thieno[2,3-bjpyridine-2-carboxylic acid methyl ester (1.0 g, 4.8 mmol), triethylamine (1.0 ml, 7.20 mmol) in dry tetrahydrofu- ran (50 ml) at 0 °C was added dropwise a solution of ethyl oxalyl chloride (0.8 g, 5.76 mmol) in dry tetrahydrofu ran (5 ml). The resulting reaction mixture was stirred at room temperature for 3 h and pored into ice water (200 ml). The precipitate was filtered off and dried jn vacuo at 50 °C affording 0.9 g (61 %) of 3-(ethoxyoxalyl- amino)-thieno[2,3-b]pyridine-2-carboxylic acid methyl ester as a solid.
The a solution of the above thieno[2,3-bjpyridine-2-carboxylic acid methyl ester (0.5 g, 1.62 mmol) in ethanol (20 ml) was added a solution of sodium hydroxide (0.2 g, 4.87 mmol) in water (10 ml). The resulting reaction mixture was stirred at room tem- perature for 18 h, acidified to pH « 4 by addition of 1 N aqueous hydrochloric acid. The precipitate was filtered off, washed with water (2 x 50 ml), diethyl ether (2 x 30 ml) and dried jn vacuo at 50 °C affording 130 mg (30 %) of the title compound as a solid. 55 M.p.: > 250 °C
Calculated for C^N S^a^ 1 x H2O ; C, 39.22 %; H, 2.30 %; N, 9.15 %. Found: C, 39.32 %; H, 2.35 %; N, 8.89 %.
EXAMPLE 2
HO y-o
OH
\L^ 0 O 7-fOxalyl-aminoVthieno[2.3-blpyrazine-6-carboxylic acid:
To a solution of 6-amino-thieno[2,3-b]pyrazine-7-carboxylic acid methyl ester (62.7 mg, 0.3 mmol) in tetrahydrofuran (0.5 ml) was added imidazol-1-yl-oxo-acetic acid tetτ-butyl ester (117.6 mg, 0.6 mmol) and triethylamine (42 μl, 0.3 mmol). The resul- ting mixture was stirred for 20 h at room temperature.
The volatiles were removed jn vacuo and the residue was dissolved in ethyl acetate (5.0 ml), washed with 1 % hydrochloric acid (2 x 2 ml), water (2 x 2 ml), dried (MgSO4), filtered and the solvent evaporated in vacuo affording 96 mg (95 %) of 6- (te/τ-butoxyoxalyl-amino)-thieno[2,3-b]pyrazine-7-carboxylic acid methyl ester as a solid.
1H NMR (400 MHz, CDCI3) δ 1.60 (s, 9H), 3.80 (s, 3H), 8.60 (d, 1H, J = 1.5 Hz), 8.70 (d, 1H, J = 1.5 Hz).
To a solution of the above 6-(tetτ-butoxyoxalyl-amino)-thieno[2,3-b]pyrazine-7- carboxylic acid methyl ester (37.8 mg, 0.112 mmol) in dioxane (1.2 ml) was added lithium hydroxide (45 mg) and water (0.6 ml) and the mixture was stirred for 20 h at room temperature. The volatiles were evaporated jn vacuo and the residue dissolved in ethyl acetate (30 ml), washed with 1.0 N hydrochloric acid (3 x 3 ml), water (3 x 3 56 ml), dried (Na2SO4), filtered and the solvent evaporated in vacuo affording 20 mg (67 %) of the tjtje compound as a solid.
1H NMR (400 MHz, CD3OD) δ 8.64 (d, 1H, J = 1.5 Hz), 8.66 (1H, d, J = 1.5 Hz). MS m/z 150.0 (M-117) loose of COOH and COCOQH.
EXAMPLE 3
o
V-OH rv« o
"s O x OH
5-(Oxalyl-amino)-2.3-dihydro-thieno[2.3-b]furan-4-carboxylic acid, mono sodium salt:
To a solution of dihydro-furan-3-one (11.5 g, 0.134 mol, prepared as described in Org. Syn. Coll. Vol. 5, 866) in ethanol (200 ml) was added ethyl cyanoacetate (16.6 g, 0.147 mol), sulfur (4.7 g, 0.147 mol) and morpholine (15 ml). The moderate exothermic reaction was stirred at 45 °C for 1 h. The reaction mixture was cooled, filtered and the filtrate evaporated in vacuo. The resultant oil was dissolved in ethyl acetate (400 ml), washed with water (2 x 100 ml), brine (100 ml) and dried (Na2SO4). The solvent was evaporated in vacjjo and the residue (28 g) was subjected to flash column chromatography (1 I silicagel) using ethyl acetate/hexanes (1:1) as eluent. Semi-pure fractions were collected affording after evaporation jn vacuo crude 8.4 g of 5-amino-2,3-dihydro-thieno[2,3-b]furan-4-carboxylic acid ethyl ester as an oil.
To the above 5-amino-2,3-dihydro-thieno[2,3-b]furan-4-carboxylic acid ethyl ester (8.4 g, 0.039 mol) dissolved in dry tetrahydrofuran (150 ml), was added triethylamine (10 ml). A mixture of ethyl oxalyl chloride (4.9 g, 0.043 mol) in dry tetrahydrofuran (25 ml) was added dropwise at 0 °C under nitrogen and the reaction mixture was allowed to stir at room temperature for 18 h. The volatiles were evaporated jn vacuo and the residue dissolved in ethyl acetate (400 ml). The organic phase was washed with water (200 ml), brine (100 ml), dried (Na2SO4), filtered and the organic phase evaporated in vacuo. The residue was filtered through a path of silicagel using a mixture of 57 ethyl acetate and heptane (1 :1) as eluent. The solvent was evaporated in vacuo and the residue was subjected to flash column chromatography (1 I silicagel) using ethyl acetate/hexanes (1 :2) as eluent. Pure fractions were collected affording after evaporation jn vacuo and washing of the residue with diethyl ether 0.5 g (1.2 %) of 5- (ethoxyoxalyl-amino)-2,3-dihydro-thieno[2,3-b]furan-4-carboxylic acid ethyl ester as an oil.
To a solution of the above 5-(ethoxyoxalyl-amino)-2,3-dihydro-thieno[2,3-b]furan-4- carboxylic acid ethyl ester (0.4 g, 1.2 mmol) in a mixture of ethanol (10 ml) and water (25 ml) was added a solution of 1 N sodium hydroxide (3.8 ml, 3.8 mmol). The mixture was stirred for 20 h at room temperature. The reaction mixture was diluted with water (50 ml) and washed with ethyl acetate (50 ml). The aqueous phase was acidified with 1 N hydrochloric acid to pH = 2. The precipitate was filtered off and washed with water, dried in vacuo at 50 °C affording 0.2 g of 5-(oxalyl-amino)-2,3-dihydro- thieno[2,3-b]furan-4-carboxylic acid ethyl ester according to NMR. The mono-ester was dissolved in a mixture of water (40 ml) and ethanol (10 ml) and to this mixture was added 1 N sodium hydroxide (3 ml, 3 mmol). The mixture was stirred for 20 h at room temperature acidified with 1 N hydrochloric acid to pH = 2 and the precipitate filtered off, washed with water and dried in vacuo at 50 °C affording 150 mg (46 %) of the title compound as a solid.
M.p.: > 250 °C.
Calculated for C9H6N S^a^ 1 * H2O ; C, 36.37 %; H, 2.71 %; N, 4.71 %. Found: C, 36.55 %; H, 2.68 %; N, 4.52 %.
1H NMR (300 MHz, DMSO-d6) δ 3.12 (t, 2H), 4.89 (t, 2H), 12.0 (bs, 1 H, NHCO).

Claims

58 CLAIMS
1. A compound of Formula 1
R17\ /R1
3 o
Formula 1
wherein A is together with the double bond in Formula 1 furo[2,3-b]pyridyl, thieno[2,3-b]pyridyl, pyrrolo[2,3-b]pyridyl, furo[2,3-c]pyridyl, thieno[2,3-c]pyridyl, pyr- rolo[2,3-c]pyridyl, furo[3,2-c]pyridyl, thieno[3,2-c]pyridyl, pyrrolo[3,2-c]pyridyl, furo[3,2-d]pyridyl, thieno[3,2-djpyridyl, pyrrolo[3,2-d]pyridyl, furo[2,3-d]pyrimidyl, thieno[2,3-d]pyrimidyl, pyrrolo[2,3-d]pyrimidyl, furo[2,3-b]pyrazinyl, thieno[2,3- bjpyrazinyl, pyrrolo[2,3-b]pyrazinyl, furo[2,3-c]pyridazinyl, thieno[2,3-c]pyridazinyl, pyrrolo[2,3-cjpyridazinyl, furo[2,3-d]pyridazinyl, thieno[2,3-d]pyridazinyl, pyrrolo[2,3- djpyridazinyl, furo[3,2-c]pyridazinyl, thieno[3,2-c]pyridazinyl, pyrrolo[3,2-c]pyridazinyl, quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxali- nyl, 1 ,8-naphthyridinyl, chromanyl, thiochromanyl, isochromanyl, isothiochromanyl, 2,3-dihydro-thieno[2,3-b]furanyl, 4,6-dihydro-thieno[2,3-c]furanyl, 2,3-dihydro- thieno[3,2-b]furanyl, 4,5-dihydro-thieno[2,3-b]thiophenyl, 4,6-dihydro-thieno[3,4- bjthiophenyl, 5,6-dihydro-thieno[3,2-b]thiophenyl, 4,5-dihydro-thieno[2,3-b]pyrrolyl, thieno[3,2-d]isothiazolyl, thieno[3,2-d]thiazolyl, thieno[2,3-d]thiazolyl, thieno[2,3- c]pyrrolyl-4,6-dione, 1H-thieno[2,3-d]imidazolyl, 6H-thieno[2,3-b]pyrrolyl, 5,6-dihydro- 4H-thieno[2,3-c]pyrrolyl or 4H-thieno[3,2-b]pyrrolyl;
R, is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 or selected from the following 5- membered heterocycles: 59 H O ┬░
N NN ┬░ r0H sVOH HN -OH HN^
N'NS-0 0M 0H S'Ny┬░H N-\-0H NN -SH -0 =N =N ^-0 ^O
N'V0H HN' 0H <cV0H rOH (f ┬░
p
*
or R. is
O R
Λ T RJ 12Y 0H^
wherein R12, R13, and R14 are independently hydrogen, C C6alkyl, aryl, arylC Cgalkyl and the alkyl and aryl groups are optionally substituted;
R2 is COR5, OR6, CF3, nitro, cyano, SO3H, SO2NR7R8, PO(OH)2, CH2PO(OH)2, CHFPO(OH)2, CF2PO(OH)2, C(=NH)NH2, NR7R8 , or selected from the following 5- membered heterocycles:
60
H -N. o-VOH s'V0H HN' 0H H ┬░N's9 -N X X X y^
N S=0 0'Y┬░H S-N^OH y =N =N frm N' V"SH
X
-N__. OH
N VOH HN -OM prw >yoH H
/ H p H,r\
R3, R16 and R17are independently hydrogen, halo, nitro, cyano, trihalomethyl, Cr C6alkyl, aryl, arylC1-C6alkyl, hydroxy, oxo, carboxy, carboxyC^Cgalkyl, G,- Cgalkyloxycarbonyl, aryloxycarbonyi, arylC C6alkyloxycarbonyl, C1-C6alkyloxy, Cr CgalkyloxyC^Cgalkyl, aryloxy, arylCϊ-Cgalkyloxy, arylC1-C6alkyloxyC1-C6alkyl, thio, C C6alkylthio, C CgalkylthioC Cgalkyl, arylthio, arylCrC6alkylthio, arylC1-C6alkylthioC1- C6alkyl, NR7R8, C1-C6alkylaminoC1-C6alkyl, arylC CgalkylaminoC Cgalkyl, di(arylCr Cgalky aminoC^-Cgalkyl, C1-C6aikylcarbonyl, C1-C6alkylcarbonyl-C1-C6alkyl, arylC^ Cgalkylcarbonyl, arylC1-CgalkylcarbonylC1-Cgalkyl, C C6alkylcarboxy, C
CgalkylcarboxyC^Cg-alkyl, arylcarboxy, arylcarboxyC1-C6alkyll arylC1-C6alkylcarboxy, arylC1-C6alkylcarboxyC1-C6alkyl, Ci-Cgalkylcarbonylamino, C C6alkylcarbonylaminoCrC6alkyl, -carbonylNR -CgalkylCOR^, arylCr C6alkylcarbonylamino, arylC1-C6alkylcarbonylaminoC1-C6alkyl, CONR7R8, or C C6alkylCONR7R8 wherein the alkyl and aryl groups are optionally substituted and R is NR7R8, or C1-C6alkylNR7R8; or R3 is
R13
Λ 1*13 H
┬╗14 R12 ┬░ 61 wherein R12, R13, and R14 are independently hydrogen, CrC6alkyl, aryl, arylC^Cgalkyl and the alkyl and aryl groups are optionally substituted;
R4 is hydrogen, hydroxy, C1-C6alkyl, aryl, arylCTCgalkyl, NR7R8, C^Cgalkyloxy; whe- rein the alkyl and aryl groups are optionally substituted;
R5 is hydroxy, CrC6alkyl, aryl, arylCrC6alkyl, CrC6alkyloxy, C1-C6alkyl-oxyC1- C6alkyloxy, aryloxy, arylC1-C6alkyloxy, CF3, NR7R8; wherein the alkyl and aryl groups are optionally substituted;
R6 is hydrogen, C C6alkyl, aryl, arylC^Cgalkyl; wherein the alkyl and aryl groups are optionally substituted;
R7 and R8 are independently selected from hydrogen, C C6alkyl, aryl, arylC^Cgalkyl, ^-Cgalkylcarbonyl, arylcarbonyl, arylC Cgalkylcarbonyl, C^Cgalkylcarboxy or arylCr C6alkylcarboxy wherein the alkyl and aryl groups are optionally substituted; or R7 and R8 are together with the nitrogen to which they are attached forming a saturated, partially saturated or aromatic cyclic, bicyclic or tricyclic ring system containing from 3 to 14 carbon atoms and from 0 to 3 additional heteroatoms selected from ni- trogen, oxygen or sulfur, the ring system can optionally be substituted with at least one C1-C6alkyl, aryl, arylCrC6alkyl, hydroxy, oxo, CrC6aIkyloxy, arylCrC6alkyloxy, C1-C6alkyloxyC1-C6alkyl, NR9R10 or C1-C6alkylaminoC1-CgaIkyl, wherein R9 and R10 are independently selected from hydrogen, C C6alkyl, aryl, arylC1-C╬▓alkyl, C C6alkylcarbonyl, arylcarbonyl, arylCrC6alkylcarbonyl, CrCgalkylcarboxy or arylCr C6alkylcarboxy; wherein the alkyl and aryl groups are optionally substituted; or
R7 and R8 are independently a saturated or partial saturated cyclic 5, 6 or 7 membe- red amine, imide or lactam;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical iso- mer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms. 62
2. A compound according to claim 1 wherein A is furo[2,3-b]pyridyl.
3. A compound according to claim 1 wherein A is thieno[2,3-b]pyridyl.
4. A compound according to claim 1 wherein A is pyrrolo[2,3-b]pyridyl.
5. A compound according to claim 1 wherein A is furo[2,3-c]pyridyl.
6. A compound according to claim 1 wherein A is thieno[2,3-c]pyridyl.
7. A compound according to claim 1 wherein A is pyrrolo[2,3-cjpyridyl.
8. A compound according to claim 1 wherein A is furo[3,2-c]pyridyl.
9. A compound according to claim 1 wherein A is thieno[3,2-c]pyridyl.
10. A compound according to claim 1 wherein A is pyrrolo[3,2-c]pyridyl.
11. A compound according to claim 1 wherein A is furo[3,2-d]pyridyl.
12. A compound according to claim 1 wherein A is thieno[3,2-d]pyridyl.
13. A compound according to claim 1 wherein A is pyrrolo[3,2-d]pyridyl.
14. A compound according to claim 1 wherein A is furo[2,3-d]pyrimidyl.
15. A compound according to claim 1 wherein A is thieno[2,3-d]pyrimidyl.
16. A compound according to claim 1 wherein A is pyrrolo[2,3-d]pyrimidyl. 63
17. A compound according to claim 1 wherein A is furo[2,3-b]pyrazinyl.
18. A compound according to claim 1 wherein A is thieno[2,3-b]pyrazinyl.
19. A compound according to claim 1 wherein A is pyrrolo[2,3-bjpyrazinyl.
20. A compound according to claim 1 wherein A is furo[2,3-c]pyridazinyl.
21. A compound according to claim 1 wherein A is thieno[2,3-c]pyridazinyl.
22. A compound according to claim 1 wherein A is pyrrolo[2,3-c]pyridazinyl.
23. A compound according to claim 1 wherein A is furo[2,3-d]pyridazinyl.
24. A compound according to claim 1 wherein A is thieno[2,3-d]pyridazinyl.
25. A compound according to claim 1 wherein A is pyrrolo[2,3-d]pyridazinyl.
26. A compound according to claim 1 wherein A is furo[3,2-c]pyridazinyl.
27. A compound according to claim 1 wherein A is thieno[3,2-c]pyridazinyl.
28. A compound according to claim 1 wherein A is pyrrolo[3,2-c]pyridazinyl.
29. A compound according to claim 1 wherein A is quinolizinyl.
30. A compound according to claim 1 wherein A is quinolinyl.
31. A compound according to claim 1 wherein A is isoquinolinyl.
32. A compound according to claim 1 wherein A is cinnolinyl. 64
33. A compound according to claim 1 wherein A is phthalazinyl.
34. A compound according to claim 1 wherein A is quinazolinyl.
35. A compound according to claim 1 wherein A is quinoxalinyl.
36. A compound according to claim 1 wherein A is1 ,8-naphthyridinyl.
37. A compound according to claim 1 wherein A is chromanyl.
38. A compound according to claim 1 wherein A is thiochromanyl.
39. A compound according to claim 1 wherein A is isochromanyl.
40. A compound according to claim 1 wherein A is isothiochromanyl.
41. A compound according to claim 1 wherein A is 2,3-dihydro-thieno[2,3- bjfuranyl.
42. A compound according to claim 1 wherein A is 4,5-dihydro-thieno[2,3- bjthiophenyl.
43. A compound according to claim 1 wherein A is 4,5-dihydro-thieno[2,3- bjpyrrolyl.
44. A compound according to claim 1 wherein A is thieno[3,2-d]isothiazolyl.
45. A compound according to claim 1 wherein A is thieno[3,2-d]thiazolyl.
46. A compound according to claim 1 wherein A is thieno[2,3-d]thiazolyl. 65
47. A compound according to claim 1 wherein A is thieno[2,3-c]pyrrolyl-4,6- dione.
48. A compound according to claim 1 wherein A is 1H-thieno[2,3-d]imidazolyl.
49. A compound according to claim 1 wherein A is 6H-thieno[2,3-b]pyrrolyl.
50. A compound according to claim 1 wherein A is 5,6-dihydro-4H-thieno[2,3- cjpyrrolyl.
51. A compound according to claim 1 wherein A is 4H-thieno[3,2-b]pyrrolyl.
52. A compound according to claim 1 wherein A is 4,6-dihydro-thieno[2,3- cjfuranyl.
53. A compound according to claim 1 wherein A is 2,3-dihydro-thieno[3,2- bjfuranyl.
54. A compound according to claim 1 wherein A is 4,6-dihydro-thieno[3,4- bjthiophenyl.
55. A compound according to claim 1 wherein A is 5,6-dihydro-thieno[3,2- bjthiophenyl.
56. A compound according to claim 2 to 55wherein R and R2 are COR5 and R4 is hydrogen; wherein R5 is defined as above.
57. A compound according to claim 2 to 55 wherein R, is 5-tetrazolyl and R2 is COR5; wherein R5 is defined as above. 66
58. A compound according to claim 2 to 55 wherein R. and R2 are COOH and R4 is hydrogen.
59. A compound selected from the following:
2-(Oxalyl-amino)-thieno[2,3-b]pyridine-3-carboxylic acid;
6-(Oxalyl-amino)-thieno[2,3-djpyrimidine-5-carboxylic acid;
6-(Oxalyl-amino)-thieno[2,3-b]pyrazine-7-carboxylic acid;
3-(Oxalyl-amino)-thieno[2,3-b]pyridine-2-carboxylic acid; 5-(Oxalyl-amino)-thieno[2,3-d]pyrimidine-6-carboxylic acid;
7-(Oxalyl-amino)-thieno[2,3-b]pyrazine-6-carboxylic acid;
5-(Oxalyl-amino)-2,3-dihydro-thieno[2,3-b]furan-4-carboxylic acid;
2-(Oxalyl-amino)-4,5-dihydro-thieno[2,3-bjthiophene-3-carboxylic acid;
5-(Oxalyl-amino)-thieno[3,2-djisothiazole-4-carboxylic acid; 5-(Oxalyl-amino)-thieno[3,2-d]thiazole-6-carboxylic acid;
5-(Oxalyl-amino)-thieno[2,3-d]thiazole-6-carboxylic acid;
2-(Oxalyl-amino)-4,6-dioxo-5,6-dihydro-4H-thieno[2,3-c]pyrrole-3-carboxylic acid;
5-(Oxalyl-amino)-1 H-thieno[2,3-d]imidazole-6-carboxylic acid;
2-(Oxalyl-amino)-6H-thieno[2,3-b]pyrrole-3-carboxylic acid; 2-(Oxalyl-amino)-5,6-dihydro-4H-thieno[2,3-c]pyrrole-3-carboxylic acid;
2-(Oxalyl-amino)-4H-thieno[3,2-bjpyrrole-3-carboxylic acid;
2-(Oxalyl-amino)-quinoiine-3-carboxylic acid;
3-(Oxalyl-amino)-quinoline-2-carboxylic acid;
4-(Oxalyl-amino)-quinoline-3-carboxylic acid; 3-(Oxalyl-amino)-quinoline-4-carboxylic acid;
5-(Oxalyl-amino)-quinoline-6-carboxylic acid;
4-(Oxalyl-amino)-isoquinoline-3-carboxylic acid;
3-(Oxalyl-amino)-isoquinoline-4-carboxylic acid;
7-(Oxalyl-amino)-quinoxaline-6-carboxylic acid; 2-(Oxalyl-amino)-[1 ,8]naphthyridine-3-carboxylic acid; 67 or a pharmaceutically acceptable salt thereof.
60. Compounds according to any one of the preceding claims which acts as inhibitors or modulators of Protein Tyrosine Phosphatases.
61. A pharmaceutical composition comprising a compound according to any of the claim 1 to 59 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms together with one or more pharmaceuti- cally acceptable carriers or diluents.
62. A pharmaceutical composition suitable for treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising a compound according to any of the claims 1 to 59 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms together with one or more pharmaceutically acceptable carriers or diluents.
63. A pharmaceutical composition suitable for treating immune dysfunctions in- eluding autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain includ- ing Alzheimer's disease and schizophrenia, and infectious diseases comprising a compound according to any of the claims 1 to 59 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms together with one or more pharmaceutically acceptable carriers or diluents. 68
64. The pharmaceutical composition according to claim 61 , 62 or 63 in the form of an oral dosage unit or parenteral dosage unit.
65. A pharmaceutical composition according to claim 61 , 62 or 63 wherein said compound is administered as a dose in a range from about 0.05 to 1000 mg, preferably from about 0.1 to 500 mg and especially in the range from 50 to 200 mg per day.
66. A compound according to any one of the claims 1 to 59 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms for therapeutical use.
67. A compound according to any one of the claims 1 to 59 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms for therapeutical use in the treatment or preventing of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity.
68. A compound according to any one of the claims 1 to 59 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms for therapeutical use in the treatment or preventing of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases. 69
69. The use of a compound according to any one of the claims 1 to 59 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms as a medicament.
70. The use of a compound according to any of the claims 1 to 59 for preparing a medicament.
71. The use of a compound according to any one of the claims 1 to 59 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms for the preparation of a medicament suitable for the treatment or preventing of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity.
72. The use of a compound according to any one of the claims 1 to 59 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms for the preparation of a medicament suitable for the treatment or preventing of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
73. A method of treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity comprising administering to a subject in need thereof an effective amount of a compound according to any of the claims 1 to 59 to said subject. 70
74. A method of treating immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases comprising administering to a subject in need thereof an effective amount of a compound according to any of the claims 1 to 59 to said subject.
75. A process for the manufacture of a medicament, particular to be used in the treatment or prevention of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance or obesity which process comprising bringing a compound according to any of the claims 1 to 59 or a pharmaceutically acceptable salt thereof into a galenic dosage form.
76. A process for the manufacture of a medicament, particular to be used in the treatment or prevention of immune dysfunctions including autoimmunity, diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases which process comprising bringing a compound according to any of the claims 1 to 59 or a pharmaceutically acceptable salt thereof into a galenic dosage form.
77. Any novel feature or combination of features as described herein.
78. A method of preparing a compound of formula 1 , characterized in 71
/Cl R
R1 H 0=< (II) ' R
.N R-
Rir^ y o
R3 X (I)
allowing an amino substituted compound of formula (I) to react with an acid chloride of formula (II), wherein A, R1 ( R2, R3, R4 R16 and R17 are defined as above, or
R15COOH + R12NH2 + RΓÇ₧CHO + R14NC ┬╗ΓÇó (I) (II) ("I) (IV)
allowing a carboxylic acid (I), a primary amine (II) and an aldehyde (III) to react with a isocyanide (IV) wherein R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, C C6alkyl, aryl, arylCrC6alkyl as defined above and the alkyl and aryl groups are optionally substituted as defined above; or R12, R13, R14, and R15 are independently selected from
i R«
wherein Y indicates attachment point for R12, R13, R14, and R15 and A, R, R2 and R4 are defined as above, or
the above described four component Ugi reaction (method b) ) is carried out by attaching any one of the components to a solid support whereby the synthesis is ac- complished in a combinatorial chemistry fashion. 72
79. Compounds according to claim 1 to 59 which acts as ligands, inhibitors or modulators of molecules with pTyr recognition units including proteins that contain SH2 domains.
EP99908770A 1998-03-12 1999-03-11 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) Withdrawn EP1062218A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
DK34898 1998-03-12
DK34898 1998-03-12
DK34698 1998-03-12
DK34698 1998-03-12
DK34798 1998-03-12
DK34798 1998-03-12
DK47598 1998-04-03
DK47698 1998-04-03
DK47498 1998-04-03
DK47498 1998-04-03
DK47698 1998-04-03
DK47598 1998-04-03
PCT/DK1999/000124 WO1999046268A1 (en) 1998-03-12 1999-03-11 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Publications (1)

Publication Number Publication Date
EP1062218A1 true EP1062218A1 (en) 2000-12-27

Family

ID=27545150

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99908770A Withdrawn EP1062218A1 (en) 1998-03-12 1999-03-11 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Country Status (4)

Country Link
EP (1) EP1062218A1 (en)
JP (1) JP2002506073A (en)
AU (1) AU2825899A (en)
WO (1) WO1999046268A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7476800A (en) * 1999-09-10 2001-04-10 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
US6410556B1 (en) 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
EP1214324B1 (en) * 1999-09-10 2006-06-14 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
EP1214325B1 (en) 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US7115624B1 (en) 1999-09-10 2006-10-03 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48
ES2436610T3 (en) 2000-01-21 2014-01-03 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
AU2001270475A1 (en) * 2000-07-07 2002-01-21 Novo-Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US6627767B2 (en) 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
EP1492780B1 (en) 2002-04-03 2011-11-23 Novartis AG 5-substituted 1,1-dioxo-¬1,2,5 thiazolidine-3-one derivatives as ptpase 1b inhibitors
AU2003239897A1 (en) 2002-05-23 2003-12-12 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
CA2536788A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005021554A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005094314A2 (en) * 2004-03-26 2005-10-13 The Burnham Institute Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
WO2006055525A2 (en) 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
CN102940638B (en) 2005-09-14 2015-03-04 武田药品工业株式会社 Dipeptidyl peptidase inhibitors for treating diabetic
NZ569607A (en) 2005-12-20 2011-06-30 Astrazeneca Ab Substituted cinnoline derivatives as GABBA-receptor modulators and method for their synthesis
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
US9074002B2 (en) 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (en) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Apoptosis signal-regulating kinase 1 inhibitors
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937719A (en) * 1975-01-06 1976-02-10 American Home Products Corporation (4-oxo-4h-1-benzopyran-2-yl)-oxamic acid, salts and esters anti-allergic agents
LU75688A1 (en) * 1976-08-31 1978-04-13
US4287126A (en) * 1980-03-10 1981-09-01 Warner-Lambert Company (2-Oxo-2H-1-benzopyran-3-yl)aminooxoacetic acids and their derivatives
US4614745A (en) * 1984-04-24 1986-09-30 Ciba-Geigy Corporation Anti-allergic 3-(carboxycarbonyl)amino benzothiopyran-4-one derivatives, compositions, and method of use therefor
US4571405A (en) * 1984-05-29 1986-02-18 Miles Laboratories, Inc. Anti-allergic chromone- or thiochromone-5-oxamic acid derivatives, compositions, and method of use therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9946268A1 *

Also Published As

Publication number Publication date
JP2002506073A (en) 2002-02-26
WO1999046268A1 (en) 1999-09-16
AU2825899A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
US6262044B1 (en) Modulators of protein tyrosine phosphatases (PTPASES)
EP1080095B1 (en) Modulators of protein tyrosine phosphatases (ptpases)
US6225329B1 (en) Modulators of protein tyrosine phosphatases (PTPases)
US20020019412A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
WO1999046268A1 (en) MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US6169087B1 (en) Modulators of protein tyrosine phosphatases (PTPases)
EP1214325B1 (en) MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
WO1999046267A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
EP1214324B1 (en) MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
WO1999046244A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
WO1999046236A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
US20020002199A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
KR20010041811A (en) Modulators of protein tyrosine phosphatases
JP2004500308A5 (en)
US20050119332A1 (en) Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US6410556B1 (en) Modulators of protein tyrosine phosphateses (PTPases)
US20030064979A1 (en) Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
EP1062199A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
EP1062204A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
AU2713999A (en) Modulators of protein tyrosine phosphatases
CZ20003229A3 (en) Compound and use thereof, pharmaceutical composition and use thereof, as well as method for adjusting activity, isolation, detection, amount determination and function of protein tyrosine phosphatases
MXPA00008921A (en) Modulators of protein tyrosine phosphatases.
CZ20003228A3 (en) Modulators of tyrosine phosphatase protein
MXPA00008927A (en) Modulators of protein tyrosine phosphatases (ptpases)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20011116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020327